{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:26:18Z","timestamp":1783031178025,"version":"3.54.6"},"update-to":[{"DOI":"10.1002\/14651858.cd012143.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T00:00:00Z","timestamp":1505692800000}}],"reference-count":773,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012143.pub3","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T21:38:35Z","timestamp":1505770715000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Direct-acting antivirals for chronic hepatitis C"],"prefix":"10.1002","volume":"2017","author":[{"given":"Janus C","family":"Jakobsen","sequence":"first","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Sjaelland Denmark DK-2100"},{"name":"Holbaek Hospital; Department of Cardiology; Holbaek Denmark 4300"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil Eik","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department 7812, Rigshospitalet, Copenhagen University Hospital; Copenhagen Trial Unit, Centre for Clinical Intervention Research; Blegdamsvej 9 Copenhagen Denmark 2100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Feinberg","sequence":"additional","affiliation":[{"name":"Rigshospitalet, Copenhagen University Hospital; Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812; Blegdamsvej 9 Copenhagen Denmark 2100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran Kumar","family":"Katakam","sequence":"additional","affiliation":[{"name":"Rigshospitalet, Copenhagen University Hospital; Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812; Blegdamsvej 9 Copenhagen Denmark 2100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Fobian","sequence":"additional","affiliation":[{"name":"Department 7812, Rigshospitalet, Copenhagen University Hospital; Copenhagen Trial Unit, Centre for Clinical Intervention Research; Blegdamsvej 9 Copenhagen Denmark 2100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Hauser","sequence":"additional","affiliation":[{"name":"Clinical Hospital Centre Rijeka; Department of Gastroenterology; Kresimirova 42 Rijeka Croatia 51 000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Poropat","sequence":"additional","affiliation":[{"name":"Clinical Hospital Centre Rijeka; Department of Gastroenterology; Kresimirova 42 Rijeka Croatia 51 000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snezana","family":"Djurisic","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Heinz","family":"Weiss","sequence":"additional","affiliation":[{"name":"Heidelberg University Hospital; Internal Medicine IV: Gastroenterology, Infectious Diseases, Toxicology; Im Neuenheimer Feld 410 Heidelberg Germany D-69120"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Bjelakovic","sequence":"additional","affiliation":[{"name":"University of Nis; Medical Faculty; Boulevard Dr Zorana Djindjica 81 Nis Serbia 18000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Bjelakovic","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of Nis; Department of Internal Medicine; Zorana Djindjica 81 Nis Serbia 18000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Louise","family":"Klingenberg","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Sjaelland Denmark DK-2100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine; Centre for Evidence-Based Chinese Medicine; 11 Bei San Huan Dong Lu, Chaoyang District Beijing China 100029"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrinka","family":"Nikolova","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Sjaelland Denmark DK-2100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L","family":"Koretz","sequence":"additional","affiliation":[{"name":"16847 Colven Road Granada Hills CA USA CA 91344"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Sjaelland Denmark DK-2100"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,18]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"e90295","DOI":"10.1371\/journal.pone.0090295","article-title":"Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C","volume":"9","author":"Brogan","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Curtis S Cure S Gavart S Dearden L Fleischmann J Ouwens M The cost-effectiveness of telaprevir (TVR) in combination with pegylated interferon-alfa and ribavirin (PR) for the treatment of genotype 1 chronic hepatitis C patients Journal of Hepatology 2012 S434","DOI":"10.1016\/S0168-8278(12)61114-3"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S908","DOI":"10.1016\/S0016-5085(11)63770-0","article-title":"Telaprevir in combination with peginterferon alfa-2a and ribavirin: analyses of pre-defined subpopulations in the phase 3 ADVANCE trial","volume":"140","author":"Bisceglie","year":"2011","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"A32","DOI":"10.1136\/gutjnl-2011-300857a.70","article-title":"Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 Advance study","volume":"60","author":"Dusheiko","year":"2011","journal-title":"Gut"},{"issue":"2S","key":"10.1002\/14651858.CD012143.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.14309\/00000434-201110002-00288","article-title":"Telaprevir in combination with peginterferon alfa-2a and ribavirin increased sustained virologic response in genotype 1 chronic HCV and allowed for shorter treatment duration in treatment-naive and prior relapser patients","volume":"106","author":"Everson","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"25","key":"10.1002\/14651858.CD012143.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0007|cit7","first-page":"427A","article-title":"Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study","volume":"52","author":"Jacobson","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0008|cit8","first-page":"879A","article-title":"Clinical virology results from telaprevir phase 3 study ADVANCE","volume":"52","author":"Kieffer","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S446","DOI":"10.1016\/S0168-8278(12)61144-1","article-title":"High concordance between SVR12 and SVR24 in patients receiving telaprevir plus peginterferon and ribavirin in three phase iii clinical trials: Advance, Illuminate and Realize","volume":"56","author":"Luo","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1016\/S0168-8278(11)60453-4","article-title":"Telaprevir in combination with peginterferon alfa-2a and ribavirin: analyses of pre-defined subpopulations in the phase 3 ADVANCE trial","volume":"54","author":"Marcellin","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S1590-8658(11)60014-5","article-title":"ADVANCE study: final results of the phase III trial with telaprevir in combination with PEG-IFN and RBV in treatment-naive genotype 1 HCV","volume":"43","author":"Rizzetto","year":"2011","journal-title":"Digestive and Liver Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/S0168-8278(11)60479-0","article-title":"Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in the Advance and Illuminate phase 3 studies","volume":"54","author":"Sulkowski","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"e90295","DOI":"10.1371\/journal.pone.0090295","article-title":"Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C","volume":"9","author":"Brogan","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Curtis S Cure S Gavart S Dearden L Fleischmann J Ouwens M The cost-effectiveness of telaprevir (TVR) in combination with pegylated interferon-alfa and ribavirin (PR) for the treatment of genotype 1 chronic hepatitis C patients Journal of Hepatology 2012 S434","DOI":"10.1016\/S0168-8278(12)61114-3"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S908","DOI":"10.1016\/S0016-5085(11)63770-0","article-title":"Telaprevir in combination with peginterferon alfa-2a and ribavirin: analyses of pre-defined subpopulations in the phase 3 ADVANCE trial","volume":"140","author":"Bisceglie","year":"2011","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"A32","DOI":"10.1136\/gutjnl-2011-300857a.70","article-title":"Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 Advance study","volume":"60","author":"Dusheiko","year":"2011","journal-title":"Gut"},{"issue":"2S","key":"10.1002\/14651858.CD012143.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.14309\/00000434-201110002-00288","article-title":"Telaprevir in combination with peginterferon alfa-2a and ribavirin increased sustained virologic response in genotype 1 chronic HCV and allowed for shorter treatment duration in treatment-naive and prior relapser patients","volume":"106","author":"Everson","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"25","key":"10.1002\/14651858.CD012143.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0019|cit19","first-page":"427A","article-title":"Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study","volume":"52","author":"Jacobson","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0020|cit20","first-page":"879A","article-title":"Clinical virology results from telaprevir phase 3 study ADVANCE","volume":"52","author":"Kieffer","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S446","DOI":"10.1016\/S0168-8278(12)61144-1","article-title":"High concordance between SVR12 and SVR24 in patients receiving telaprevir plus peginterferon and ribavirin in three phase iii clinical trials: Advance, Illuminate and Realize","volume":"56","author":"Luo","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1016\/S0168-8278(11)60453-4","article-title":"Telaprevir in combination with peginterferon alfa-2a and ribavirin: analyses of pre-defined subpopulations in the phase 3 ADVANCE trial","volume":"54","author":"Marcellin","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S1590-8658(11)60014-5","article-title":"ADVANCE study: final results of the phase III trial with telaprevir in combination with PEG-IFN and RBV in treatment-naive genotype 1 HCV","volume":"43","author":"Rizzetto","year":"2011","journal-title":"Digestive and Liver Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/S0168-8278(11)60479-0","article-title":"Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in the Advance and Illuminate phase 3 studies","volume":"54","author":"Sulkowski","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s11136-013-0519-1","article-title":"Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial","volume":"23","author":"Anderson","year":"2014","journal-title":"Quality of Life Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S523","DOI":"10.1016\/S0168-8278(11)61329-9","article-title":"The effect of IL28B polymorphisms on virologic response to treatment with pegylated interferon alpha-2A and ribavirin (SOC) added to ABT-450\/ritonavir (ABT-450\/R), ABT-333, or ABT-072","volume":"54","author":"Gaultier","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/S0168-8278(11)61231-2","article-title":"Genotypic and phenotypic characterization of NS3 variants selected in HCV-infected patients treated with ABT-450","volume":"54","author":"Pilot-Matias","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s11136-013-0519-1","article-title":"Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial","volume":"23","author":"Anderson","year":"2014","journal-title":"Quality of Life Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S523","DOI":"10.1016\/S0168-8278(11)61329-9","article-title":"The effect of IL28B polymorphisms on virologic response to treatment with pegylated interferon alpha-2A and ribavirin (SOC) added to ABT-450\/ritonavir (ABT-450\/R), ABT-333, or ABT-072","volume":"54","author":"Gaultier","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/S0168-8278(11)61231-2","article-title":"Genotypic and phenotypic characterization of NS3 variants selected in HCV-infected patients treated with ABT-450","volume":"54","author":"Pilot-Matias","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s11136-013-0519-1","article-title":"Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial","volume":"23","author":"Anderson","year":"2014","journal-title":"Quality of Life Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S523","DOI":"10.1016\/S0168-8278(11)61329-9","article-title":"The effect of IL28B polymorphisms on virologic response to treatment with pegylated interferon alpha-2A and ribavirin (SOC) added to ABT-450\/ritonavir (ABT-450\/R), ABT-333, or ABT-072","volume":"54","author":"Gaultier","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/S0168-8278(11)61231-2","article-title":"Genotypic and phenotypic characterization of NS3 variants selected in HCV-infected patients treated with ABT-450","volume":"54","author":"Pilot-Matias","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s11136-013-0519-1","article-title":"Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial","volume":"23","author":"Anderson","year":"2014","journal-title":"Quality of Life Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"S523","DOI":"10.1016\/S0168-8278(11)61329-9","article-title":"The effect of IL28B polymorphisms on virologic response to treatment with pegylated interferon alpha-2A and ribavirin (SOC) added to ABT-450\/ritonavir (ABT-450\/R), ABT-333, or ABT-072","volume":"54","author":"Gaultier","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/S0168-8278(11)61231-2","article-title":"Genotypic and phenotypic characterization of NS3 variants selected in HCV-infected patients treated with ABT-450","volume":"54","author":"Pilot-Matias","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s11136-013-0519-1","article-title":"Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial","volume":"23","author":"Anderson","year":"2014","journal-title":"Quality of Life Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S523","DOI":"10.1016\/S0168-8278(11)61329-9","article-title":"The effect of IL28B polymorphisms on virologic response to treatment with pegylated interferon alpha-2A and ribavirin (SOC) added to ABT-450\/ritonavir (ABT-450\/R), ABT-333, or ABT-072","volume":"54","author":"Gaultier","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/S0168-8278(11)61231-2","article-title":"Genotypic and phenotypic characterization of NS3 variants selected in HCV-infected patients treated with ABT-450","volume":"54","author":"Pilot-Matias","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s11136-013-0519-1","article-title":"Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial","volume":"23","author":"Anderson","year":"2014","journal-title":"Quality of Life Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"S523","DOI":"10.1016\/S0168-8278(11)61329-9","article-title":"The effect of IL28B polymorphisms on virologic response to treatment with pegylated interferon alpha-2A and ribavirin (SOC) added to ABT-450\/ritonavir (ABT-450\/R), ABT-333, or ABT-072","volume":"54","author":"Gaultier","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/S0168-8278(11)61231-2","article-title":"Genotypic and phenotypic characterization of NS3 variants selected in HCV-infected patients treated with ABT-450","volume":"54","author":"Pilot-Matias","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s11136-013-0519-1","article-title":"Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial","volume":"23","author":"Anderson","year":"2014","journal-title":"Quality of Life Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"S523","DOI":"10.1016\/S0168-8278(11)61329-9","article-title":"The effect of IL28B polymorphisms on virologic response to treatment with pegylated interferon alpha-2A and ribavirin (SOC) added to ABT-450\/ritonavir (ABT-450\/R), ABT-333, or ABT-072","volume":"54","author":"Gaultier","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/S0168-8278(11)61231-2","article-title":"Genotypic and phenotypic characterization of NS3 variants selected in HCV-infected patients treated with ABT-450","volume":"54","author":"Pilot-Matias","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s11136-013-0519-1","article-title":"Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial","volume":"23","author":"Anderson","year":"2014","journal-title":"Quality of Life Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"S523","DOI":"10.1016\/S0168-8278(11)61329-9","article-title":"The effect of IL28B polymorphisms on virologic response to treatment with pegylated interferon alpha-2A and ribavirin (SOC) added to ABT-450\/ritonavir (ABT-450\/R), ABT-333, or ABT-072","volume":"54","author":"Gaultier","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/S0168-8278(11)61231-2","article-title":"Genotypic and phenotypic characterization of NS3 variants selected in HCV-infected patients treated with ABT-450","volume":"54","author":"Pilot-Matias","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0049|cit49","unstructured":"NCT01247194 A phase 1b study of PPI-461 in patients with HCV genotype 1 clinicaltrials.gov\/ct2\/show\/study\/NCT01247194?term=NCT01247194&rank=1"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0050|cit50","unstructured":"NCT01247194 A phase 1b study of PPI-461 in patients with HCV genotype 1 clinicaltrials.gov\/ct2\/show\/study\/NCT01247194?term=NCT01247194&rank=1"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0051|cit51","unstructured":"NCT01247194 A phase 1b study of PPI-461 in patients with HCV genotype 1 clinicaltrials.gov\/ct2\/show\/study\/NCT01247194?term=NCT01247194&rank=1"},{"issue":"Suppl 199","key":"10.1002\/14651858.CD012143.pub3-BIB0052|cit52","first-page":"15S","article-title":"Safety of simeprevir (SMV) with peg Ifnalpha-2a\/ribavirin (PR) in HCV genotype 1-infected patients: PILLAR and ASPIRE trials","volume":"143","author":"Ferenci","year":"2013","journal-title":"Swiss Medical Weekly"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0168-8278(12)60023-3","article-title":"TMC435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon\/ribavirin treatment: virologic analyses of the ASPIRE trial","volume":"56","author":"Lenz","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/1471-2334-14-465","article-title":"Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection","volume":"14","author":"Scott","year":"2014","journal-title":"BMC Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"A216","DOI":"10.1016\/j.jval.2013.03.1094","article-title":"Fatigue severity scale: reliability, validity and interpretation of change-evidence from two clinical trials in patients with chronic HCV infection","volume":"16","author":"Scott","year":"2013","journal-title":"Value in Health"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0056|cit56","first-page":"S371","article-title":"Adding simeprevir (TMC435) to pegylated interferon\/ribavirin does not increase patient reported fatigue in treatment-experienced patients with chronic HCV infection: results from the ASPIRE trial","volume":"58","author":"Scott","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","article-title":"Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial","volume":"146","author":"Zeuzem","year":"2014","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.1016\/S0168-8278(11)61378-0","article-title":"The ASPIRE trial: TMC435 in treatment-experienced patients with genotype-1 HCV infection who have failed previous PEGIFN\/RBV treatment","volume":"54","author":"Zeuzem","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1053\/j.gastro.2013.06.051","article-title":"Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-na\u00efve patients with hepatitis C virus genotype 1 infection","volume":"145","author":"Marcellin","year":"2013","journal-title":"Gastroenterology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1016\/S0168-8278(12)61204-5","article-title":"High sustained virological response rates with response-guided danoprevir plus peginterferon alfa-2a (40KD) and ribavirin in treatment-naive, HCV genotype 1 patients: ATLAS study final results","volume":"56","author":"Marcellin","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0061|cit61","first-page":"398A","article-title":"High sustained virologic response (SVR24) rates with response-guided danoprevir (DNV; RG7227) plus pegIfn alpha-2A (40KD) and ribavirin (P\/R) in treatment-naive HCV genotype 1 (G1) patients: results from the ATLAS study","volume":"54","author":"Terrault","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0062|cit62","first-page":"335A","article-title":"Phase II randomised, partially-blind, parallel-group study of oral danoprevir (RG7227) with PegIFN\u03b1-2a (Pegasys) plus ribavirin (Copegus) in treatment-naive genotype 1 patients with CHC: results of planned week 12 interim analysis of the ATLAS study","volume":"52","author":"Terrault","year":"2010","journal-title":"Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0063|cit63","first-page":"376A","article-title":"Predictors of sustained virologic response (SVR) among poor interferon (IFN) responders when boceprevir (BOC) is added to peginterferon alfa-2b\/ribavirin (PR)","volume":"54","author":"Bacon","year":"2011","journal-title":"Hepatology"},{"issue":"13","key":"10.1002\/14651858.CD012143.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0065|cit65","first-page":"430A","article-title":"HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon\/ribavirin when re-treated with boceprevir plus PEGINTRON (peginterferon alfa-2b)\/ribavirin","volume":"52","author":"Bacon","year":"2010","journal-title":"Hepatology"},{"issue":"1-2","key":"10.1002\/14651858.CD012143.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2013.06.029","article-title":"Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies","volume":"444","author":"Barnard","year":"2013","journal-title":"Virology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD012143.pub3-BIB0067|cit67","first-page":"161","article-title":"Boceprevir (BOC) plus peginterferon alfa-2b\/ ribavirin (PR) in the treatment of chronic hepatitis C virus genotype-1 (HCV-G1) infected Asian patients in the SPRINT-1, SPRINT-2 and RESPOND-2 trials","volume":"27","author":"Bognar","year":"2012","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S471","DOI":"10.1016\/S0168-8278(11)61196-3","article-title":"Sustained virologic response and boceprevir resistance-associated variants observed in patients infected with HCV genotpype Ia\/Ib when treated with boceprevir plus peginterferon alfa-2b\/ribavirin","volume":"54","author":"Brass","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(11)60009-3","article-title":"Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus (HCV) genotype-1 with advanced fibrosis\/cirrhosis: subgroup analysis of sprint-2 and respond-2 studies","volume":"54","author":"Bruno","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2012.11.020","article-title":"Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis\/cirrhosis","volume":"58","author":"Bruno","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jval.2013.07.006","article-title":"Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States","volume":"16","author":"Chhatwal","year":"2013","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/S0168-8278(11)60411-X","article-title":"Projecting the long-term clinical impact of boceprevir in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon\/ribavirin","volume":"54","author":"Chhatwal","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"4 (Suppl)","key":"10.1002\/14651858.CD012143.pub3-BIB0073|cit73","first-page":"801A","article-title":"Cost-effectiveness of boceprevir use in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon\/ribavirin","volume":"54","author":"Chhatwal","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"S386","DOI":"10.1016\/S0168-8278(12)61001-0","article-title":"Cost-effectiveness of boceprevir in the treatment of chronic Hepatitis C genotype 1 in Sweden","volume":"56","author":"Chhatwal","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0075|cit75","first-page":"848A","article-title":"Reasons for screen failure in 2 phase III studies of boceprevir with peginterferon\/ribavirin in patients with chronic HCV genotype 1 infection (sprint-2 and respond-2)","volume":"54","author":"Gordon","year":"2011","journal-title":"Hepatology"},{"issue":"4 (Suppl)","key":"10.1002\/14651858.CD012143.pub3-BIB0076|cit76","first-page":"985A","article-title":"TMC435 in combination with peginterferon alpha-2A\/ribavirin in treatment-na\u00efve patients infected with HCV genotype 1: virology analysis of the PILLAR study","volume":"54","author":"Lenz","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/S0168-8278(11)60454-6","article-title":"Efficacy among North American and European HCV genotype-1 treatment-naive and previous non-responders and relapsers to peginterferon\/ribavirin when treated with boceprevir plus peginterferon alfa-2b\/ribavirin","volume":"54","author":"Marcellin","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0078|cit78","first-page":"198","article-title":"Boceprevir combined with peginterferon alfa-2b\/ribavirin for previous treatment failure patients with hepatitis C virus genotype 1: RESPOND-2 final results","volume":"10","author":"Sulkowski","year":"2011","journal-title":"Journal of the International Association of Physicians in AIDS Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1016\/S0168-8278(11)60486-8","article-title":"Predictors of sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon\/ribavirin when re-treated with boceprevir plus peginterferon alfa-2b\/ribavirin","volume":"54","author":"Zeuzem","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0080|cit80","first-page":"376A","article-title":"Predictors of sustained virologic response (SVR) among poor interferon (IFN) responders when boceprevir (BOC) is added to peginterferon alfa-2b\/ribavirin (PR)","volume":"54","author":"Bacon","year":"2011","journal-title":"Hepatology"},{"issue":"13","key":"10.1002\/14651858.CD012143.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0082|cit82","first-page":"430A","article-title":"HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon\/ribavirin when re-treated with boceprevir plus PEGINTRON (peginterferon alfa-2b)\/ribavirin","volume":"52","author":"Bacon","year":"2010","journal-title":"Hepatology"},{"issue":"1-2","key":"10.1002\/14651858.CD012143.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2013.06.029","article-title":"Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies","volume":"444","author":"Barnard","year":"2013","journal-title":"Virology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD012143.pub3-BIB0084|cit84","first-page":"161","article-title":"Boceprevir (BOC) plus peginterferon alfa-2b\/ ribavirin (PR) in the treatment of chronic hepatitis C virus genotype-1 (HCV-G1) infected Asian patients in the SPRINT-1, SPRINT-2 and RESPOND-2 trials","volume":"27","author":"Bognar","year":"2012","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"S471","DOI":"10.1016\/S0168-8278(11)61196-3","article-title":"Sustained virologic response and boceprevir resistance-associated variants observed in patients infected with HCV genotpype Ia\/Ib when treated with boceprevir plus peginterferon alfa-2b\/ribavirin","volume":"54","author":"Brass","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(11)60009-3","article-title":"Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus (HCV) genotype-1 with advanced fibrosis\/cirrhosis: subgroup analysis of sprint-2 and respond-2 studies","volume":"54","author":"Bruno","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2012.11.020","article-title":"Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis\/cirrhosis","volume":"58","author":"Bruno","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jval.2013.07.006","article-title":"Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States","volume":"16","author":"Chhatwal","year":"2013","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/S0168-8278(11)60411-X","article-title":"Projecting the long-term clinical impact of boceprevir in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon\/ribavirin","volume":"54","author":"Chhatwal","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"4 (Suppl)","key":"10.1002\/14651858.CD012143.pub3-BIB0090|cit90","first-page":"801A","article-title":"Cost-effectiveness of boceprevir use in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon\/ribavirin","volume":"54","author":"Chhatwal","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"S386","DOI":"10.1016\/S0168-8278(12)61001-0","article-title":"Cost-effectiveness of boceprevir in the treatment of chronic Hepatitis C genotype 1 in Sweden","volume":"56","author":"Chhatwal","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0092|cit92","first-page":"848A","article-title":"Reasons for screen failure in 2 phase III studies of boceprevir with peginterferon\/ribavirin in patients with chronic HCV genotype 1 infection (sprint-2 and respond-2)","volume":"54","author":"Gordon","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/S0168-8278(11)60454-6","article-title":"Efficacy among North American and European HCV genotype-1 treatment-naive and previous non-responders and relapsers to peginterferon\/ribavirin when treated with boceprevir plus peginterferon alfa-2b\/ribavirin","volume":"54","author":"Marcellin","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0094|cit94","first-page":"198","article-title":"Boceprevir combined with peginterferon alfa-2b\/ribavirin for previous treatment failure patients with hepatitis C virus genotype 1: RESPOND-2 final results","volume":"10","author":"Sulkowski","year":"2011","journal-title":"Journal of the International Association of Physicians in AIDS Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1016\/S0168-8278(11)60486-8","article-title":"Predictors of sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon\/ribavirin when re-treated with boceprevir plus peginterferon alfa-2b\/ribavirin","volume":"54","author":"Zeuzem","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 2","key":"10.1002\/14651858.CD012143.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.14309\/00000434-201410002-00606","article-title":"Simeprevir and sofosbuvir with modified doses of ribavirin (RBV) therapy on telaprevir-experienced, coinfected (with HIV) cirrhotics with chronic hepatitis C (CHC): a randomized, open-label, clinical pilot study, STOP C, interim results","volume":"109","author":"Basu","year":"2014","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0097|cit97","first-page":"46","article-title":"Interferon ineligible naive chronic hepatitis C genotype I subjects treated with simeprevir and sofosbuvir in special population (psychiatric). A clinical pilot study; Inspire C study; interim results","volume":"17","author":"Basu","year":"2015","journal-title":"HPB: the Official Journal of the International Hepato Pancreato Biliary Association"},{"issue":"4 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0098|cit98","first-page":"255A","article-title":"Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5b polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects","volume":"46","author":"Bavisotto","year":"2007","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0099|cit99","first-page":"722A","article-title":"Antiviral response and resistance analysis of treatment-naive HCV infected subjects receiving single and multiple doses of GS - 9190","volume":"52","author":"Harris","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/infdis\/jit274","article-title":"Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial","volume":"208","author":"Benhamou","year":"2013","journal-title":"Journal of Infectious Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(09)60012-X","article-title":"Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon ALFA-2A and ribavirin in treatment-naive genotype 4 HCV patients","volume":"50","author":"Benhamou","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0102|cit102","first-page":"719A","article-title":"Activity of telaprevir monotherapy or in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 4 hepatitis C patients: final results of study C210","volume":"52","author":"Benhamou","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1743-422X-11-93","article-title":"Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir","volume":"11","author":"Meyer","year":"2014","journal-title":"Virology Journal"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/infdis\/jit274","article-title":"Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial","volume":"208","author":"Benhamou","year":"2013","journal-title":"Journal of Infectious Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(09)60012-X","article-title":"Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon ALFA-2A and ribavirin in treatment-naive genotype 4 HCV patients","volume":"50","author":"Benhamou","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0106|cit106","first-page":"719A","article-title":"Activity of telaprevir monotherapy or in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 4 hepatitis C patients: final results of study C210","volume":"52","author":"Benhamou","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1743-422X-11-93","article-title":"Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir","volume":"11","author":"Meyer","year":"2014","journal-title":"Virology Journal"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0108|cit108","unstructured":"Boehringer Ingelheim Safety, antiviral activity, and pharmcokinetics of multiple rising oral doses of BI201334 NA in treatment-naive patients with chronic hepatitis C infection for 14 days monotherapy followed by combination with pegylated interferon and ribavirin for an additional 14 days (double-blind, placebo controlled); and in treatment experienced patients with chronic hepatitis C infection for 28 days as combination therapy with pegylated interferon and ribavirin (open label) www.trials.boehringer-ingelheim.com\/public\/trial_results_documents\/1220\/1220.2_U10-2363-01_PE_DS_DR.pdf"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0109|cit109","unstructured":"Boehringer Ingelheim A randomised, double-blind, placebo controlled trial with 200 mg BILN 2061ZW given p.o. at two consecutive days bid to investigate the antiviral efficacy, pharmacokinetics, safety in patients with cirrhosis and chronic hepatitis C www.trials.boehringer-ingelheim.com\/public\/trial_results_documents\/605\/605.9_U03-1671.pdf"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0110|cit110","first-page":"S431","article-title":"Asunaprevir (ASV; BMS-650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection","volume":"56","author":"Bronowicki","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1016\/S0168-8278(11)61197-5","article-title":"BMS-650032, an NS3 inhibitor, in combination with peginterferon alpha-2a and ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C infection","volume":"54","author":"Bronowicki","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3851\/IMP2660","article-title":"Randomized study of asunaprevir plus pegylated interferon-alpha and ribavirin for previously untreated genotype 1 chronic hepatitis C","volume":"18","author":"Bronowicki","year":"2013","journal-title":"Antiviral Therapy"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0113|cit113","first-page":"S431","article-title":"Asunaprevir (ASV; BMS-650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection","volume":"56","author":"Bronowicki","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1016\/S0168-8278(11)61197-5","article-title":"BMS-650032, an NS3 inhibitor, in combination with peginterferon alpha-2a and ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C infection","volume":"54","author":"Bronowicki","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3851\/IMP2660","article-title":"Randomized study of asunaprevir plus pegylated interferon-alpha and ribavirin for previously untreated genotype 1 chronic hepatitis C","volume":"18","author":"Bronowicki","year":"2013","journal-title":"Antiviral Therapy"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0116|cit116","first-page":"S431","article-title":"Asunaprevir (ASV; BMS-650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection","volume":"56","author":"Bronowicki","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1016\/S0168-8278(11)61197-5","article-title":"BMS-650032, an NS3 inhibitor, in combination with peginterferon alpha-2a and ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C infection","volume":"54","author":"Bronowicki","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3851\/IMP2660","article-title":"Randomized study of asunaprevir plus pegylated interferon-alpha and ribavirin for previously untreated genotype 1 chronic hepatitis C","volume":"18","author":"Bronowicki","year":"2013","journal-title":"Antiviral Therapy"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jhep.2014.07.011","article-title":"Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C","volume":"61","author":"Bronowicki","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0120|cit120","first-page":"S431","article-title":"Asunaprevir (ASV; BMS-650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection","volume":"56","author":"Bronowicki","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"S571","DOI":"10.1016\/S0168-8278(13)61419-1","article-title":"Asunaprevir with peginterferon-alfa and ribavirin in treatment-naive patients with genotype-1 or -4 chronic hepatitis C: SVR24 results from a randomized phase 2B study (AI447016)","volume":"58","author":"Bronowicki","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0122|cit122","first-page":"227A","article-title":"C-edge Co-star: efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy","volume":"62","author":"Dore","year":"2015","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0123|cit123","first-page":"565A","article-title":"C-EDGE TN: Impact of 12-week oral regimen of grazoprevir (GZR, MK-5172)\/Elbasvir (EBR, MK-8742) on patient-reported outcomes (PROs) in treatment-naive patients with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infection","volume":"62","author":"Arduino","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Annals of Internal Medicine"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1016\/S0168-8278(15)30056-8","article-title":"The phase 3 C-EDGE treatment-naive (TN) study of a 12-week oral regimen of grazoprevir (GZR, mk-5172)\/ elbasvir (EBR, mk-8742) in patients with chronic HCV genotype (GT) 1, 4, or 6 infection","volume":"62","author":"Zeuzem","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"4 (Suppl 2)","key":"10.1002\/14651858.CD012143.pub3-BIB0126|cit126","first-page":"A748","article-title":"Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in patients with chronic hepatitis C virus: preliminary results from a randomized, double-blind, placebo-controlled, ascending multiple dose study - first article","volume":"130","author":"Chandra","year":"2006","journal-title":"Gastroenterology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0127|cit127","first-page":"474A","article-title":"BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results","volume":"54","author":"Hezode","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0128|cit128","first-page":"167","article-title":"Daclatasvir (BMS-790052), a NS5A replication complex inhibitor, combined with peginterferon-alfa-2a and ribavirin in treatment-naive HCV genotype 1 or 4 subjects: phase 2b AI444010 study interim week 24 results","volume":"6","author":"Hezode","year":"2012","journal-title":"Hepatology International"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/gutjnl-2014-307498","article-title":"Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study","volume":"64","author":"Hezode","year":"2015","journal-title":"Gut"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0130|cit130","first-page":"474A","article-title":"BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results","volume":"54","author":"Hezode","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0131|cit131","first-page":"167","article-title":"Daclatasvir (BMS-790052), a NS5A replication complex inhibitor, combined with peginterferon-alfa-2a and ribavirin in treatment-naive HCV genotype 1 or 4 subjects: phase 2b AI444010 study interim week 24 results","volume":"6","author":"Hezode","year":"2012","journal-title":"Hepatology International"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/gutjnl-2014-307498","article-title":"Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study","volume":"64","author":"Hezode","year":"2015","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jhep.2014.04.004","article-title":"Simeprevir with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial","volume":"61","author":"Hayashi","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"4 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0134|cit134","first-page":"864A","article-title":"Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic hepatitis C patients: results from a randomized, double-blind, placebo-controlled, ascending multiple dose study","volume":"46","author":"Cooper","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2009.03.015","article-title":"Evaluation of VCH-759 monotherapy in hepatitis C infection","volume":"51","author":"Cooper","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/liv.12471","article-title":"Dauphine: a randomized phase II study of danoprevir\/ritonavir plus peginterferon alpha-2a\/ribavirin in HCV genotypes 1 or 4","volume":"35","author":"Everson","year":"2015","journal-title":"Liver International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1016\/S0168-8278(12)61189-1","article-title":"Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir-boosted danoprevir\/peg-ifna-2a\/RBV in HCV genotype 1 or 4 patients: dauphine week 12 interim analysis","volume":"56","author":"Everson","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0138|cit138","first-page":"557A","article-title":"Ritonavir-boosted danoprevir plus peg-IFNalpha-2a\/ribavirin (P\/R) demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment-naive patients with HCV genotype 4 infection in the DAUPHINE study","volume":"56","author":"Hezode","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1016\/S0168-8278(12)61203-3","article-title":"Low rate of on-treatment resistance to danoprevir boosted by ritonavir (DNVR) combined with Peg-IFNa-2a\/ribavirin: 12 week interim analysis from Dauphine study","volume":"56","author":"Pogam","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/liv.12471","article-title":"Dauphine: a randomized phase II study of danoprevir\/ritonavir plus peginterferon alpha-2a\/ribavirin in HCV genotypes 1 or 4","volume":"35","author":"Everson","year":"2015","journal-title":"Liver International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1016\/S0168-8278(12)61189-1","article-title":"Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir-boosted danoprevir\/peg-ifna-2a\/RBV in HCV genotype 1 or 4 patients: dauphine week 12 interim analysis","volume":"56","author":"Everson","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0142|cit142","first-page":"557A","article-title":"Ritonavir-boosted danoprevir plus peg-IFNalpha-2a\/ribavirin (P\/R) demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment-naive patients with HCV genotype 4 infection in the DAUPHINE study","volume":"56","author":"Hezode","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1016\/S0168-8278(12)61203-3","article-title":"Low rate of on-treatment resistance to danoprevir boosted by ritonavir (DNVR) combined with peg-IFNa-2a\/ribavirin: 12 week interim analysis from Dauphine study","volume":"56","author":"Pogam","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/liv.12471","article-title":"Dauphine: a randomized phase II study of danoprevir\/ritonavir plus peginterferon alpha-2a\/ribavirin in HCV genotypes 1 or 4","volume":"35","author":"Everson","year":"2015","journal-title":"Liver International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1016\/S0168-8278(12)61189-1","article-title":"Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir-boosted danoprevir\/peg-ifna-2a\/RBV in HCV genotype 1 or 4 patients: dauphine week 12 interim analysis","volume":"56","author":"Everson","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0146|cit146","first-page":"557A","article-title":"Ritonavir-boosted danoprevir plus peg-IFNalpha-2a\/ribavirin (P\/R) demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment-naive patients with HCV genotype 4 infection in the DAUPHINE study","volume":"56","author":"Hezode","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1016\/S0168-8278(12)61203-3","article-title":"Low rate of on-treatment resistance to danoprevir boosted by ritonavir (DNVR) combined with peg-IFNa-2a\/ribavirin: 12 week interim analysis from Dauphine study","volume":"56","author":"Pogam","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/liv.12471","article-title":"Dauphine: a randomized phase II study of danoprevir\/ritonavir plus peginterferon alpha-2a\/ribavirin in HCV genotypes 1 or 4","volume":"35","author":"Everson","year":"2015","journal-title":"Liver International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1016\/S0168-8278(12)61189-1","article-title":"Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir-boosted danoprevir\/peg-ifna-2a\/RBV in HCV genotype 1 or 4 patients: dauphine week 12 interim analysis","volume":"56","author":"Everson","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0150|cit150","first-page":"557A","article-title":"Ritonavir-boosted danoprevir plus peg-IFNalpha-2a\/ribavirin (P\/R) demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment-naive patients with HCV genotype 4 infection in the DAUPHINE study","volume":"56","author":"Hezode","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1016\/S0168-8278(12)61203-3","article-title":"Low rate of on-treatment resistance to danoprevir boosted by ritonavir (DNVR) combined with Peg-IFNa-2a\/ribavirin: 12 week interim analysis from Dauphine study","volume":"56","author":"Pogam","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/hep.23899","article-title":"Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients","volume":"52","author":"Bruijne","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/S0168-8278(10)60748-9","article-title":"Narlaprevir and peginterferon alfa-2b for 2 weeks in chronic hepatitis C genotype 1 patients, followed by peginterferon alfa-2b and ribavirin for 24\/48 weeks: final results","volume":"52","author":"Bruijne","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1111\/jvh.12012","article-title":"Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up","volume":"20","author":"Hotho","year":"2013","journal-title":"Journal of Viral Hepatitis"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/hep.23899","article-title":"Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients","volume":"52","author":"Bruijne","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/S0168-8278(10)60748-9","article-title":"Narlaprevir and peginterferon alfa-2b for 2 weeks in chronic hepatitis C genotype 1 patients, followed by peginterferon alfa-2b and ribavirin for 24\/48 weeks: final results","volume":"52","author":"Bruijne","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1111\/jvh.12012","article-title":"Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up","volume":"20","author":"Hotho","year":"2013","journal-title":"Journal of Viral Hepatitis"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1016\/S0168-8278(11)60460-1","article-title":"Final results of the pharmacokinetics, efficacy, and safety\/tolerability of 400 and 600 mg once-daily dosing of ACH-1625 (HCV NS3 protease inhibitor) in HCV genotype 1","volume":"54","author":"Detishin","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2014.10.007","article-title":"Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection","volume":"148","author":"Dore","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2014.10.007","article-title":"Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection","volume":"148","author":"Dore","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00535-013-0875-1","article-title":"Once-daily simeprevir (TMC435) with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study","volume":"49","author":"Hayashi","year":"2014","journal-title":"Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00535-013-0875-1","article-title":"Once-daily simeprevir (TMC435) with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study","volume":"49","author":"Hayashi","year":"2014","journal-title":"Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00535-013-0875-1","article-title":"Once-daily simeprevir (TMC435) with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study","volume":"49","author":"Hayashi","year":"2014","journal-title":"Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00535-013-0875-1","article-title":"Once-daily simeprevir (TMC435) with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study","volume":"49","author":"Hayashi","year":"2014","journal-title":"Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/135965350901400104","article-title":"Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment","volume":"14","author":"Erhardt","year":"2009","journal-title":"Antiviral Therapy"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0168-8278(14)60062-3","article-title":"Sapphire I: Phase 3 placebo-controlled study of interferon-free, 12-week regimen of ABT-450\/R\/ABT-267, ABT-333, and ribavirin in 631 treatment-naive adults with hepatitis Cvirus genotype 1","volume":"60","author":"Feld","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"17","key":"10.1002\/14651858.CD012143.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"S912","DOI":"10.1016\/S0016-5085(14)63320-5","article-title":"Sapphire I: Phase 3 placebo-controlled study of interferon-free, 12-week regimen of ABT-450\/R\/ABT-267, ABT-333, and ribavirin in 631 treatment-naive adults with hepatitis C virus genotype 1","volume":"146","author":"Kowdley","year":"2014","journal-title":"Gastroenterology"},{"issue":"27","key":"10.1002\/14651858.CD012143.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD012143.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2013.12.006","article-title":"Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C)","volume":"60","author":"Younossi","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"S541","DOI":"10.1016\/S0168-8278(11)61368-8","article-title":"High sustained virologic response (SVR) among genotype 1 previous non-responders and relapsers to peginterferon\/ribavirin when re-treated with boceprevir (BOC) plus peginterferon alfa-2A\/ribavirin","volume":"54","author":"Flamm","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cgh.2012.10.006","article-title":"Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection","volume":"11","author":"Flamm","year":"2013","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0174|cit174","first-page":"443A","article-title":"Analysis of sustained viral response and boceprevir resistance following combination treatment with boceprevir plus peginterferon alfa-2A\/ribavirin in HCV genotype 1 prior relapsers and non-responders","volume":"54","author":"Howe","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/hep.21774","article-title":"Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C","volume":"46","author":"Forestier","year":"2007","journal-title":"Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD012143.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1055\/s-2007-988479","article-title":"Status of patients with chronic hepatitis C after a 14-day pre-treatment with Telaprevir (VX-950) followed by an anti-viral therapy with Peg-interferon-alpha-2a (Peg-IFN-2a) and Ribavirin (RBV)","volume":"45","author":"Forestier","year":"2007","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-2008-1037655","article-title":"Status of patients with chronic hepatitis C after a pretreatment period of 14 days with Telaprevir (VX-950) und a following antiviral therapy with Peg-interferon-alfa-2a (Peg-IFN-2s) and ribavirin (RBV)","volume":"46","author":"Forestier","year":"2008","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"4 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0178|cit178","first-page":"614A","article-title":"Current status of subjects receiving peg-interferon-alfa-2A (peg-ifn) and ribavirin (RBV) after a 14-day study of the hepatitis C protease inhibitor telaprevir (VX-950), with peg-ifn","volume":"44","author":"Forestier","year":"2006","journal-title":"Hepatology"},{"issue":"4 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0179|cit179","first-page":"819A","article-title":"Final results of patients receiving peg-interferon-alfa-2a (Peg-IFN) and ribavirin (RBV) after a 14-day study of the hepatitis C protease inhibitor telaprevir (VX-950), with Peg-IFN","volume":"46","author":"Weegink","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jhep.2010.11.001","article-title":"Treatment of chronic hepatitis C patients with the NS3\/4A protease inhibitor danoprevir (ITMN-191\/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study","volume":"54","author":"Forestier","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"4 (Suppl)","key":"10.1002\/14651858.CD012143.pub3-BIB0181|cit181","first-page":"1132A","article-title":"Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3\/4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: results of a phase 1b multiple ascending dose (MAD) study","volume":"48","author":"Forestier","year":"2008","journal-title":"Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD012143.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1136\/gut.2010.219089","article-title":"Danoprevir, an HCV NS3\/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C","volume":"59","author":"Moucari","year":"2010","journal-title":"Gut"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jhep.2010.11.001","article-title":"Treatment of chronic hepatitis C patients with the NS3\/4A protease inhibitor danoprevir (ITMN-191\/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study","volume":"54","author":"Forestier","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"4 (Suppl)","key":"10.1002\/14651858.CD012143.pub3-BIB0184|cit184","first-page":"1132A","article-title":"Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3\/4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: results of a phase 1b multiple ascending dose (MAD) study","volume":"48","author":"Forestier","year":"2008","journal-title":"Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD012143.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1136\/gut.2010.219089","article-title":"Danoprevir, an HCV NS3\/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C","volume":"59","author":"Moucari","year":"2010","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0168-8278(09)60087-8","article-title":"Antiviral activity and safety of ITMN-191 in combination with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV)","volume":"50","author":"Forestier","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/infdis\/jir315","article-title":"Antiviral activity of danoprevir (ITMN-191\/RG7227) in combination with pegylated interferon alpha-2a and ribavirin in patients with hepatitis C","volume":"204","author":"Forestier","year":"2011","journal-title":"Journal of Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"issue":"4 SUPPL. 1","key":"10.1002\/14651858.CD012143.pub3-BIB0189|cit189","first-page":"737A","article-title":"Simeprevir (TMC435) with peg-interferon alpha-2a\/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III trial","volume":"58","author":"Forns","year":"2013","journal-title":"Hepatology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0190|cit190","first-page":"S181","article-title":"Simeprevir (TMC435) with peg-interferon alpha-2a\/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy in patients with genotype 1b HCV in the PROMISE phase III trial","volume":"8","author":"Gane","year":"2014","journal-title":"Hepatology International"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/S0016-5085(13)60542-9","article-title":"Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial","volume":"144","author":"Lawitz","year":"2013","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/jvh.12046","article-title":"Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes","volume":"20","author":"Meyer","year":"2013","journal-title":"Journal of Viral Hepatitis"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0193|cit193","first-page":"A118","article-title":"Analyses of genotype 2\/3 HCV variants in patients treated with telaprevir in study C209 showed that the telaprevir resistance profile appears to be consistent across genotypes","volume":"15","author":"Meyer","year":"2010","journal-title":"Antiviral Therapy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0195|cit194","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0168-8278(10)60059-1","article-title":"Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: final results of STUDY C209","volume":"52","author":"Foster","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0194|cit195","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/j.gastro.2011.05.046","article-title":"Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections","volume":"141","author":"Foster","year":"2011","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/jvh.12046","article-title":"Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes","volume":"20","author":"Meyer","year":"2013","journal-title":"Journal of Viral Hepatitis"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0197|cit197","first-page":"A118","article-title":"Analyses of genotype 2\/3 HCV variants in patients treated with telaprevir in study C209 showed that the telaprevir resistance profile appears to be consistent across genotypes","volume":"15","author":"Meyer","year":"2010","journal-title":"Antiviral Therapy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0199|cit198","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0168-8278(10)60059-1","article-title":"Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: final results of STUDY C209","volume":"52","author":"Foster","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0198|cit199","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/j.gastro.2011.05.046","article-title":"Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections","volume":"141","author":"Foster","year":"2011","journal-title":"Gastroenterology"},{"issue":"27","key":"10.1002\/14651858.CD012143.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"27","key":"10.1002\/14651858.CD012143.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0168-8278(11)60013-5","article-title":"Impact of IL28B genotype and pretreatment serum IP-10 in treatment-naive genotype-1 HCV patients treated with TMC435 in combination with peginterferona-2A and ribavirin in PILLAR study","volume":"54","author":"Aerssens","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0203|cit203","first-page":"403A","article-title":"Efficacy and safety of TMC435 in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype-1 HCV patients: 24-week interim results from the PILLAR study","volume":"52","author":"Fried","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-na\u00efve genotype 1 hepatitis C: the randomized PILLAR study","volume":"58","author":"Fried","year":"2013","journal-title":"Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"A362","DOI":"10.1016\/j.jval.2013.08.230","article-title":"Patients with chronic hepatitis C virus treated with simeprevir added to peginterferon and ribavirin experienced less time with fatigue, depressive symptoms, and functional limitations: results from patients in the QUEST-1, QUEST-2, and promise studies","volume":"16","author":"Scott","year":"2013","journal-title":"Value in Health"},{"issue":"8","key":"10.1002\/14651858.CD012143.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/jvh.12365","article-title":"Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 and PROMISE studies","volume":"22","author":"Scott","year":"2015","journal-title":"Journal of Viral Hepatitis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0207|cit207","first-page":"S371","article-title":"Improved SVR with simeprevir (TMC435) associated with reduced time with patient-reported fatigue in treatment-naive, HCV-infected patients in the PILLAR phase IIb trial","volume":"58","author":"Scott","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0208|cit208","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/jvh.12360","article-title":"Alisporivir with peginterferon\/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a phase II trial","volume":"22","author":"Buti","year":"2014","journal-title":"Journal of Viral Hepatitis"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0209|cit209","first-page":"S206","article-title":"Superior SVR24 rates with alisporivir (ALV) plus peg-interferon\/ribavirin (P\/R) in chronic HCV hepatitis (CHC) genotype 1 (G1) prior P\/R treatment failures: final results of the fundamental study","volume":"8","author":"Chuang","year":"2014","journal-title":"Hepatology International"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0210|cit210","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/jvh.12360","article-title":"Alisporivir with peginterferon\/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a phase II trial","volume":"22","author":"Buti","year":"2014","journal-title":"Journal of Viral Hepatitis"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0211|cit211","first-page":"S206","article-title":"Superior SVR24 rates with alisporivir (ALV) plus peg-interferon\/ribavirin (P\/R) in chronic HCV hepatitis (CHC) genotype 1 (G1) prior P\/R treatment failures: Final results of the fundamental study","volume":"8","author":"Chuang","year":"2014","journal-title":"Hepatology International"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/jvh.12360","article-title":"Alisporivir with peginterferon\/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a phase II trial","volume":"22","author":"Buti","year":"2014","journal-title":"Journal of Viral Hepatitis"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0213|cit213","first-page":"S206","article-title":"Superior SVR24 rates with alisporivir (ALV) plus peg-interferon\/ribavirin (P\/R) in chronic HCV hepatitis (CHC) genotype 1 (G1) prior P\/R treatment failures: Final results of the fundamental study","volume":"8","author":"Chuang","year":"2014","journal-title":"Hepatology International"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0214|cit214","first-page":"1024A","article-title":"Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500mg BID with PEG-IFN and ribavirin for 28 days","volume":"48","author":"Gane","year":"2008","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0168-8278(08)60068-9","article-title":"Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with peg-IFN and ribavirin: interim results of R7128 500MG bid for 28 days","volume":"48","author":"Lalezari","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1016\/S0168-8278(11)61325-1","article-title":"The effect of host IL28B genotype on early viral kinetics during interferon-free treatment in patients with chronic hepatitis C (CHC)","volume":"54","author":"Chu","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1016\/S0168-8278(09)61048-5","article-title":"First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227\/ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM-1","volume":"50","author":"Gane","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0218|cit218","first-page":"394A","article-title":"Combination therapy with a nucleoside polymerase (R7128) and protease (R7227\/ITMN - 191) inhibitor in HCV: safety, pharmacokinetics, and virologic results from INFORM-1","volume":"50","author":"Gane","year":"2009","journal-title":"Hepatology"},{"issue":"9751","key":"10.1002\/14651858.CD012143.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"376","author":"Gane","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD012143.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1128\/AAC.01035-12","article-title":"Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3\/4 protease inhibitor danoprevir","volume":"56","author":"Pogam","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.24432","article-title":"A glimpse at the future of hepatitis C therapy: The INFORM trial","volume":"54","author":"Lim","year":"2011","journal-title":"Hepatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0222|cit222","first-page":"1041A","article-title":"Pharmacokinetics\/pharmacodynamics (PK\/PD) of combination R7227 and R7128 therapy from INFORM-1 demonstrates similar early HCV viral dynamics when R7227 is combined with either PEG - IFN\/ribavirin (SOC) or R7128","volume":"50","author":"Morcos","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0223|cit223","first-page":"S16","article-title":"Ritonavir boosting of low dose RG7227\/ITMN-191, HCV NS3\/4 a protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens","volume":"52","author":"Gane","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jhep.2011.01.046","article-title":"Antiviral activity, safety, and pharmacokinetics of danoprevir\/ritonavir plus PEG-IFN alpha-2a\/RBV in hepatitis C patients","volume":"55","author":"Gane","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD012143.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s00228-013-1556-y","article-title":"A randomised study of the effect of danoprevir\/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail","volume":"69","author":"Morcos","year":"2013","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1016\/S0168-8278(15)30160-4","article-title":"Sustained virologic response after ACH-3102 and sofosbuvir treatment for 8 or 6 weeks: A phase 2 \"proxy\" study","volume":"62","author":"Gane","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1111\/liv.12334","article-title":"A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects","volume":"34","author":"Gardner","year":"2014","journal-title":"Liver International"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0228|cit228","unstructured":"GlaxoSmithKline plc A randomized, single blind, dose escalation, placebo-controlled study to assess the safety, pharmacokinetics, and antiviral activity of repeat doses of GSK2878175 in subjects with chronic hepatitis C www.gsk-clinicalstudyregister.com\/files2\/116976-Clinical-Study-Result-Summary.pdf"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0229|cit229","first-page":"717A","article-title":"Safety, pharmacokinetics, and antiviral activity of single oral doses of the HCV NS3 protease inhibitor GS 9256","volume":"52","author":"Goldwater","year":"2010","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0230|cit230","first-page":"S278","article-title":"Safety and tolerability of daclatasvir (DCV) in patients with chronic HCV infection","volume":"9","author":"Jacobson","year":"2015","journal-title":"Hepatology International"},{"issue":"9954","key":"10.1002\/14651858.CD012143.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multi cohort study","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0232|cit232","first-page":"S222","article-title":"Boceprevir plus peginterferon alfa and ribavirin for Korean patients with chronic hepatitis C virus genotype 1 infection and previous treatment failure","volume":"8","author":"Han","year":"2014","journal-title":"Hepatology International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0168-8278(12)61106-4","article-title":"100% SVR in IL28B CC patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial","volume":"56","author":"Bronowicki","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(08)60060-4","article-title":"Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon-alfa-2a with or without ribavirin: further interim analysis results of the PROVE2 study","volume":"48","author":"Dusheiko","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"4, Suppl. 1","key":"10.1002\/14651858.CD012143.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"A755","DOI":"10.1016\/S0016-5085(08)63525-8","article-title":"Prove2 Study: treatment of chronic hepatitis C with telaprevir (Tvr) in combination with peginterferon-alfa-2a with or without ribavirin, interim analysis results","volume":"134","author":"Hezode","year":"2008","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1002\/14651858.CD012143.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0237|cit237","first-page":"s395","article-title":"SVR4 results for the combination of ACH-3102 and sovaprevir, with ribavirin, in subjects with genotype 1 chronic hepatitis C infection","volume":"8","author":"Muir","year":"2014","journal-title":"Hepatology International"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0238|cit238","first-page":"862A","article-title":"Evaluation of viral variants during a phase 2 study (PROVE2) of telaprevir with peginterferon alfa-2A and ribavirin in treatment-na\u00efve HCV genotype 1-infected patients","volume":"46","author":"Pawlotsky","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0239|cit239","first-page":"169","article-title":"PROVE2: a phase 2b study of telaprevir combined with peginterferon-alfa-2a with or without ribavirin for treatment-naive patients with chronic hepatitis C","volume":"3","author":"Pawlotsky","year":"2009","journal-title":"Hepatology International"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0240|cit240","first-page":"418A","article-title":"Telaprevir in combination with peginterferon-alfa-2a with or without ribavirin in the treatment of chronic hepatitis C: final results of the PROVE2 study","volume":"48","author":"Zeuzem","year":"2008","journal-title":"Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0241|cit241","first-page":"268A","article-title":"PROVE2: phase II study of VX950 (telaprevir) in combination with peginterferon alfa2A with or without ribavirin in subjects with chronic hepatitis C; first interim analysis","volume":"46","author":"Zeuzem","year":"2007","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"1347-55","DOI":"10.1053\/j.gastro.2004.08.002","article-title":"Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients","volume":"127","author":"Hinrichsen","year":"2004","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"297A","DOI":"10.1016\/S0270-9139(03)80337-3","article-title":"Safety and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, and liver cirrhosis","volume":"38","author":"Wedemeyer","year":"2003","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0244|cit244","first-page":"S71","article-title":"Simeprevir exposure in Asian treatment naive patients with chronic hepatitis C virus genotype 1 infection results from a population pharmacokinetic model in the phase III Tiger study","volume":"9","author":"Hoeben","year":"2015","journal-title":"Hepatology International"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0245|cit245","first-page":"S61","article-title":"Simeprevir plus peginterferon ribavirin in treatment naive patients with chronic hepatitis C virus genotype 1 infection results from the phase III Tiger study conducted in East Asian patients living in China and Korea","volume":"9","author":"Wei","year":"2015","journal-title":"Hepatology International"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0246|cit246","first-page":"S71","article-title":"Simeprevir exposure in Asian treatment naive patients with chronic hepatitis C virus genotype 1 infection results from a population pharmacokinetic model in the phase III Tiger study","volume":"9","author":"Hoeben","year":"2015","journal-title":"Hepatology International"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0247|cit247","first-page":"S61","article-title":"Simeprevir plus peginterferon ribavirin in treatment naive patients with chronic hepatitis C virus genotype 1 infection results from the phase III Tiger study conducted in East Asian patients living in China and Korea","volume":"9","author":"Wei","year":"2015","journal-title":"Hepatology International"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0248|cit248","first-page":"1031A","article-title":"Accelerated clinical trial design to assess the safety, tolerability and anti-viral activity of PHX1766, a novel HCV NS3\/4A protease inhibitor, in healthy volunteers and chronic hepatitis C patients","volume":"50","author":"Hotho","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3851\/IMP1989","article-title":"Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design","volume":"17","author":"Hotho Daphne","year":"2012","journal-title":"Antiviral Therapy"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4254\/wjh.v8.i6.331","article-title":"Boceprevir plus peginterferon\/ribavirin for treatment of chronic hepatitis C in Russia","volume":"8","author":"Isakov","year":"2016","journal-title":"World Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0251|cit251","first-page":"1439A","article-title":"Combination therapy of treatment-naive and nonresponder patients with HCV genotype 1 infection with BMS-790052, an NS5A replication complex inhibitor, in combination with peginterferon alfa-2a and ribavirin","volume":"54","author":"Izumi","year":"2011","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3851\/IMP2731","article-title":"Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1","volume":"19","author":"Izumi","year":"2014","journal-title":"Antiviral Therapy"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3851\/IMP2729","article-title":"Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b","volume":"19","author":"McPhee","year":"2014","journal-title":"Antiviral Therapy"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0254|cit254","first-page":"1441A","article-title":"BMS-790052, AN NS5A replication complex inhibitor, in combination with peginterferon alpha-2B and ribavirin in Japanese treatment naive and nonresponder patients with chronic HCV genotype 1 infection","volume":"54","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0255|cit255","first-page":"161","article-title":"Daclatasvir (BMS-790052), an NS5A replication complex inhibitor, in combination with peginterferon alpha-2b and ribavirin in Japanese treatment-naive and nonresponder patients with chronic HCV genotype 1 infection","volume":"6","author":"Suzuki","year":"2012","journal-title":"Hepatology International"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3851\/IMP2730","article-title":"A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection","volume":"19","author":"Suzuki","year":"2014","journal-title":"Antiviral Therapy"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0257|cit257","first-page":"1439A","article-title":"Combination therapy of treatment-naive and nonresponder patients with HCV genotype 1 infection with BMS-790052, an NS5A replication complex inhibitor, in combination with peginterferon alfa-2a and ribavirin","volume":"54","author":"Izumi","year":"2011","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3851\/IMP2731","article-title":"Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1","volume":"19","author":"Izumi","year":"2014","journal-title":"Antiviral Therapy"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3851\/IMP2729","article-title":"Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b","volume":"19","author":"McPhee","year":"2014","journal-title":"Antiviral Therapy"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0260|cit260","first-page":"1441A","article-title":"BMS-790052, AN NS5A replication complex inhibitor, in combination with peginterferon alpha-2B and ribavirin in Japanese treatment naive and nonresponder patients with chronic HCV genotype 1 infection","volume":"54","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0261|cit261","first-page":"161","article-title":"Daclatasvir (BMS-790052), an NS5A replication complex inhibitor, in combination with peginterferon alpha-2b and ribavirin in Japanese treatment-naive and nonresponder patients with chronic HCV genotype 1 infection","volume":"6","author":"Suzuki","year":"2012","journal-title":"Hepatology International"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3851\/IMP2730","article-title":"A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection","volume":"19","author":"Suzuki","year":"2014","journal-title":"Antiviral Therapy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"S382","DOI":"10.1016\/S0168-8278(09)61054-0","article-title":"Antiviral activity of filibuvir in combination with pegylated interferon alfa-2A and ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1","volume":"50","author":"Jacobson","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0264|cit264","first-page":"S464","article-title":"Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa-2A and ribavirin in chronically-infected HCV genotype-1 patients","volume":"52","author":"Jacobson","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0265|cit265","first-page":"722A","article-title":"Genotypic characterisation of filibuvir (PF-00868554 ) resistance in patients receiving four weeks co-administration of filibuvir with pegIFN\/RBV","volume":"52","author":"Mori","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0168-8278(10)60037-2","article-title":"Genotypic characterisation of filibuvir (PF-00868554) resistance in patients receiving four weeks co-administration of filibuvir with PEGIFN\/RBV (12 week analysis)","volume":"52","author":"Mori","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1016\/S0168-8278(13)61424-5","article-title":"Simeprevir (TMC435) with peginterferon\/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a phase III trial","volume":"58","author":"Jacobson","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"9941","key":"10.1002\/14651858.CD012143.pub3-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.26275","article-title":"JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a\/ribavirin for 24 weeks in treatment-na\u00efve HCV genotype 1\/4 patients","volume":"58","author":"Pockros","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(09)60006-4","article-title":"HCV Sprint-1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron (peginterferon ALFA-2B)\/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C","volume":"50","author":"Kwo","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"9742","key":"10.1002\/14651858.CD012143.pub3-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0272|cit272","first-page":"387","article-title":"Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-alpha2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial","volume":"18","author":"Ogert","year":"2013","journal-title":"Antiviral Therapy"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0273|cit273","first-page":"770A","article-title":"Hemogloblin decline during lead-in phase as an early predictor of anemia after the addition of boceprevir: a retrospective analysis of HCV SPRINT-1","volume":"52","author":"Poordad","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0274|cit274","first-page":"702A","article-title":"Frequencies of resistance-associated amino acid variants following combination treatment with boceprevir plus PEGINTRON (peginterferon alfa-2b)\/ribavirin in patients with chronic hepatitis C (CHC), genotype 1 (G1)","volume":"52","author":"Vierling","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(09)60006-4","article-title":"HCV sprint-1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron (peginterferon ALFA-2B)\/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C","volume":"50","author":"Kwo","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"9742","key":"10.1002\/14651858.CD012143.pub3-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0277|cit277","first-page":"387","article-title":"Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-alpha2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial","volume":"18","author":"Ogert","year":"2013","journal-title":"Antiviral Therapy"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0278|cit278","first-page":"770A","article-title":"Hemogloblin decline during lead-in phase as an early predictor of anemia after the addition of boceprevir: a retrospective analysis of HCV SPRINT-1","volume":"52","author":"Poordad","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0279|cit279","first-page":"702A","article-title":"Frequencies of resistance-associated amino acid variants following combination treatment with boceprevir plus PEGINTRON (peginterferon alfa-2b)\/ribavirin in patients with chronic hepatitis C (CHC), genotype 1 (G1)","volume":"52","author":"Vierling","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(09)60006-4","article-title":"HCV Sprint-1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron (peginterferon ALFA-2B)\/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C","volume":"50","author":"Kwo","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"9742","key":"10.1002\/14651858.CD012143.pub3-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0282|cit282","first-page":"387","article-title":"Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-alpha2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial","volume":"18","author":"Ogert","year":"2013","journal-title":"Antiviral Therapy"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0283|cit283","first-page":"770A","article-title":"Hemogloblin decline during lead-in phase as an early predictor of anemia after the addition of boceprevir: a retrospective analysis of HCV SPRINT-1","volume":"52","author":"Poordad","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0284|cit284","first-page":"702A","article-title":"Frequencies of resistance-associated amino acid variants following combination treatment with boceprevir plus PEGINTRON (peginterferon alfa-2b)\/ribavirin in patients with chronic hepatitis C (CHC), genotype 1 (G1)","volume":"52","author":"Vierling","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(09)60006-4","article-title":"HCV Sprint-1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron (peginterferon ALFA-2B)\/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C","volume":"50","author":"Kwo","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"9742","key":"10.1002\/14651858.CD012143.pub3-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0287|cit287","first-page":"387","article-title":"Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-alpha2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial","volume":"18","author":"Ogert","year":"2013","journal-title":"Antiviral Therapy"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0288|cit288","first-page":"770A","article-title":"Hemogloblin decline during lead-in phase as an early predictor of anemia after the addition of boceprevir: a retrospective analysis of HCV SPRINT-1","volume":"52","author":"Poordad","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0289|cit289","first-page":"702A","article-title":"Frequencies of resistance-associated amino acid variants following combination treatment with boceprevir plus PEGINTRON (peginterferon alfa-2b)\/ribavirin in patients with chronic hepatitis C (CHC), genotype 1 (G1)","volume":"52","author":"Vierling","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0290|cit290","first-page":"992A","article-title":"High rapid virologic response (RVR) with ach-1625 daily dosing plus pegifn-alpha 2a\/RBV in a 28-day phase 2a trial","volume":"54","author":"Lalezari","year":"2011","journal-title":"Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD012143.pub3-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"6372","DOI":"10.1128\/AAC.01521-12","article-title":"Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection","volume":"56","author":"Lalezari","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3851\/IMP2552","article-title":"IDX184 in combination with pegylated interferon-alpha2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C","volume":"18","author":"Lalezari","year":"2013","journal-title":"Antiviral Therapy"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/S0168-8278(10)61204-4","article-title":"Antiviral activity, pharmacokinetics and safety of IDX184 in combination with pegylated interferon (pegIFN) and ribavirin (RBV) in treatment-naive HCV genotype 1-infected subjects","volume":"52","author":"Lalezari","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0294|cit294","first-page":"337A","article-title":"A phase IIA study of IDX184 in combination with pegylated interferon (PEGIFN) and ribavirin (RBV) in treatment-naive HCV genotype 1-infected subjects","volume":"52","author":"Lalezari","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1016\/S0168-8278(10)61198-1","article-title":"4 week therapy with the non-nucleosidic polymerase inhibitor BI207127 in combination with peginterferon-alfa2A and ribavirin in treatment naive and treatment experienced chronic HCV GT1 patients","volume":"52","author":"Larrey","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2012.02.015","article-title":"Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin","volume":"57","author":"Larrey","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0297|cit297","first-page":"1205A","article-title":"Genotypic and phenotypic analysis of the NS5B polymerase region from viral isolates of HCV chronically infected patients treated with BI 207127 for 5-days monotherapy","volume":"52","author":"Lagace","year":"2010","journal-title":"Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD012143.pub3-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1128\/AAC.00565-13","article-title":"Antiviral effect, safety, and pharmacokinetics of five-day oral administration of deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C","volume":"57","author":"Larrey","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0299|cit299","first-page":"1044A","article-title":"BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C","volume":"50","author":"Larrey","year":"2009","journal-title":"Hepatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0300|cit300","first-page":"403A","article-title":"Safety, tolerability and antiviral activity of MK-7009, a novel inhibitor of the hepatitis C virus NS3\/4A protease, in patients with chronic HCV genotype 1 infection","volume":"48","author":"Lawitz","year":"2008","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0168-8278(09)60094-5","article-title":"Safety, tolerability and antiviral activity of VCH-916, a novel non-nucleoside HCV polymerase inhibitor in patients with chronic HCV genotype-1 infection","volume":"50","author":"Lawitz","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1016\/S0168-8278(10)61199-3","article-title":"Dose-ranging, three-day monotherapy study of the HCV NS3 protease inhibitor GS-9256","volume":"52","author":"Lawitz","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0303|cit303","first-page":"1205A","article-title":"Clinical synergy of an anti-HCV nucleoside analog with SOC: viral kinetics of PSI-7977 with SOC","volume":"52","author":"Lawitz","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0304|cit304","first-page":"334A","article-title":"Safety and antiviral activity of ANA598 in combination with pegylated interferon alpha2A plus ribavirin in treatment-naive genotype-1 chronic HCV patients","volume":"52","author":"Lawitz","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1016\/S0168-8278(10)61200-7","article-title":"Safety and antiviral activity of ANA598 in combination with pegylated interferon alpha2a plus ribavirin in treatment-naive genotype-1 chronic HCV patients","volume":"52","author":"Lawitz","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0306|cit306","first-page":"1200A","article-title":"IL28B polymorphism and kinetics of antiviral activity for ANA598 in combination with pegylated interferon \u03b12A plus ribavirin in treatment-na\u00efve genotype-1 chronic HCV patients","volume":"52","author":"Muir","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"S482","DOI":"10.1016\/S0168-8278(11)61222-1","article-title":"ABT-450\/ritonavir (ABT-450\/R) combined with pegylated interferon alpha-2a and ribavirin (SOC) after 3-day monotherapy in genotype 1 HCV-infected treatment-naive subjects: 12-week interim efficacy and safety results","volume":"54","author":"Lawitz","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0308|cit308","first-page":"878A","article-title":"4-week virologic response and safety of ABT-450 given with low-dose ritonavir (ABT-450\/r) in combination with pegylated interferon alpha-2a and ribavirin (SOC) after 3-day monotherapy in genotype 1 (GT1) HCV infected treatment-naive subjects","volume":"52","author":"Lawitz","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1016\/S0168-8278(11)60447-9","article-title":"A phase 2b trial comparing 24 to 48 weeks treatment with tegobuvir (GS-9190)\/PEG\/RBV to 48 weeks treatment with PEG\/RBV for chronic genotype 1 HCV infection","volume":"54","author":"Lawitz","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C","volume":"57","author":"Lawitz","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0311|cit311","first-page":"S470","article-title":"GS-6620, a liver-targeted nucleotide prodrug, exhibits antiviral activity and favorable safety profile over 5 days in treatment naive chronic HCV genotype 1 subjects","volume":"56","author":"Lawitz","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","article-title":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial","volume":"13","author":"Lawitz","year":"2013","journal-title":"Lancet Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","article-title":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial","volume":"13","author":"Lawitz","year":"2013","journal-title":"Lancet Infectious Diseases"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0314|cit314","first-page":"714A","article-title":"Three-day, dose-ranging study of the HCV NS3 protease inhibitor GS-9451","volume":"52","author":"Lawitz","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3851\/IMP2415","article-title":"A phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3\/4a protease inhibitor, in genotype 1 hepatitis C patients","volume":"18","author":"Lawitz","year":"2013","journal-title":"Antiviral Therapy"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1016\/S0168-8278(13)61199-X","article-title":"Resistance analysis of cirrhotic treatment-experienced genotype 1 patients in a study of MK-7009 in combination with pegylated interferon\/ribavirin","volume":"58","author":"Barnard","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0317|cit317","first-page":"S354","article-title":"Projected long-term impact of MK-7009 (vaniprevir) for previously treated chronic HCV genotype 1 infection","volume":"7","author":"Elbasha","year":"2013","journal-title":"Hepatology International"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0318|cit318","first-page":"739A","article-title":"Vaniprevir (MK-7009) demonstrates higher exposures in treatment-experienced genotype (GT) 1 cirrhotic than non-cirrhotic HCV-infected patients","volume":"58","author":"Gao","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2013.02.008","article-title":"A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment","volume":"59","author":"Lawitz","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1016\/S0168-8278(12)61191-X","article-title":"Impact of IL28B genotype on virologic response in prior treatment failure patients who received MK-7009 in combination with peginterferon and ribavirin","volume":"56","author":"Mobashery","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1128\/AAC.01263-12","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection","volume":"57","author":"Lawitz","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.antiviral.2013.05.015","article-title":"Characterization of vaniprevir, a hepatitis C virus NS3\/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics","volume":"99","author":"Lawitz","year":"2013","journal-title":"Antiviral Research"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1016\/S0168-8278(13)60849-1","article-title":"ACH-2684 demonstrates potent viral suppression in genotype 1 hepatitis C patients with and without cirrhosis: safety, pharmacokinetic, and viral kinetic analysis","volume":"58","author":"Lawitz","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0324|cit324","first-page":"1143A","article-title":"High rates of SVR in patients with genotype 1 HCV infection and cirrhosis after treatment with ledipasvir\/sofosbuvir+ribavirin or ledipasvir\/sofosbuvir+ GS-9669 for 8 weeks","volume":"59","author":"Lawitz","year":"2014","journal-title":"Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD012143.pub3-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/jvh.12435","article-title":"A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus","volume":"22","author":"Lawitz","year":"2015","journal-title":"Journal of Viral Hepatitis"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0326|cit326","first-page":"731A","article-title":"GS-5816, a once-daily NS5A inhibitor, demonstrates potent antiviral activity in patients with genotype 1, 2, 3, or 4 HCV infection in a 3-day monotherapy study","volume":"58","author":"Lawitz","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"435A","DOI":"10.1016\/S0168-8278(13)61061-2","article-title":"Resistance analysis of genotype-1 and -3 HCV-infected patients receiving MK-8742, a HCV NS5A inhibitor with potent antiviral activity","volume":"58","author":"Liu","year":"2013","journal-title":"Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD012143.pub3-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1128\/AAC.01390-15","article-title":"Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0329|cit329","first-page":"438A","article-title":"MK-8742, a HCV NS5A inhibitor with a broad spectrum of HCV genotypic activity, demonstrates potent antiviral activity in genotype-1 and -3 HCV-infected patients","volume":"58","author":"Yeh","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/S0168-8278(09)61057-6","article-title":"Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients","volume":"50","author":"Lawitz","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD012143.pub3-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.clinthera.2014.10.002","article-title":"Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor","volume":"36","author":"Mallalieu","year":"2014","journal-title":"Clinical Therapeutics"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0332|cit332","first-page":"1023A","article-title":"Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in treatment-naive patients with chronic hepatitis C genotype-1 infection given as monotherapy and in combination with peginterferon alfa 2a (P) and ribavirin (R)","volume":"48","author":"Manns","year":"2008","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jhep.2010.08.040","article-title":"Potency, safety, and pharmacokinetics of the NS3\/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection","volume":"54","author":"Manns","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.antiviral.2013.05.015","article-title":"Characterization of vaniprevir, a hepatitis C virus NS3\/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics","volume":"99","author":"Lawitz","year":"2013","journal-title":"Antiviral Research"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.25743","article-title":"Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study","volume":"56","author":"Manns","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/S0168-8278(09)61058-8","article-title":"MK-7009 significantly improves rapid viral response (RVR) in combination with pegylated interferon ALFA-2A and ribavirin in patients with chronic hepatitis C (CHC) genotype 1 infection","volume":"50","author":"Manns","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.25743","article-title":"Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study","volume":"56","author":"Manns","year":"2012","journal-title":"Hepatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0338|cit338","first-page":"332A","article-title":"Early viral response (EVR) rates in treatment - naive patients with chronic hepatitis C (CHC) genotype 1 infection treated with MK-7009, a novel NS3\/4a protease inhibitor, in combination with pegylated interferon alfa-2a and ribavirin for 28 days","volume":"50","author":"Manns","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0339|cit339","first-page":"361A","article-title":"Sustained viral response (SVR) rates in genotype 1 treatment-naive patients with chronic hepatitis C (CHC) infection treated with vaniprevir (MK-7009), A NS3\/4A protease inhibitor, in combination with pegylated interferon alfa-2a and ribavirin for 28 days","volume":"52","author":"Manns","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.antiviral.2013.05.015","article-title":"Characterization of vaniprevir, a hepatitis C virus NS3\/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics","volume":"99","author":"Lawitz","year":"2013","journal-title":"Antiviral Research"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.25743","article-title":"Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study","volume":"56","author":"Manns","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/S0168-8278(09)61058-8","article-title":"MK-7009 significantly improves rapid viral response (RVR) in combination with pegylated interferon ALFA-2A and ribavirin in patients with chronic hepatitis C (CHC) genotype 1 infection","volume":"50","author":"Manns","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.25743","article-title":"Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study","volume":"56","author":"Manns","year":"2012","journal-title":"Hepatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0344|cit344","first-page":"332A","article-title":"Early viral response (EVR) rates in treatment - naive patients with chronic hepatitis C (CHC) genotype 1 infection treated with MK-7009, a novel NS3\/4a protease inhibitor, in combination with pegylated interferon alfa-2a and ribavirin for 28 days","volume":"50","author":"Manns","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0345|cit345","first-page":"361A","article-title":"Sustained viral response (SVR) rates in genotype 1 treatment-naive patients with chronic hepatitis C (CHC) infection treated with vaniprevir (MK-7009), A NS3\/4A protease inhibitor, in combination with pegylated interferon alfa-2a and ribavirin for 28 days","volume":"52","author":"Manns","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.antiviral.2013.05.015","article-title":"Characterization of vaniprevir, a hepatitis C virus NS3\/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics","volume":"99","author":"Lawitz","year":"2013","journal-title":"Antiviral Research"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.25743","article-title":"Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study","volume":"56","author":"Manns","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/S0168-8278(09)61058-8","article-title":"MK-7009 significantly improves rapid viral response (RVR) in combination with pegylated interferon ALFA-2A and ribavirin in patients with chronic hepatitis C (CHC) genotype 1 infection","volume":"50","author":"Manns","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.25743","article-title":"Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study","volume":"56","author":"Manns","year":"2012","journal-title":"Hepatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0350|cit350","first-page":"332A","article-title":"Early viral response (EVR) rates in treatment - naive patients with chronic hepatitis C (CHC) genotype 1 infection treated with MK-7009, a novel NS3\/4a protease inhibitor, in combination with pegylated interferon alfa-2a and ribavirin for 28 days","volume":"50","author":"Manns","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0351|cit351","first-page":"361A","article-title":"Sustained viral response (SVR) rates in genotype 1 treatment-naive patients with chronic hepatitis C (CHC) infection treated with vaniprevir (MK-7009), A NS3\/4A protease inhibitor, in combination with pegylated interferon alfa-2a and ribavirin for 28 days","volume":"52","author":"Manns","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.antiviral.2013.05.015","article-title":"Characterization of vaniprevir, a hepatitis C virus NS3\/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics","volume":"99","author":"Lawitz","year":"2013","journal-title":"Antiviral Research"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.25743","article-title":"Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study","volume":"56","author":"Manns","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/S0168-8278(09)61058-8","article-title":"MK-7009 significantly improves rapid viral response (RVR) in combination with pegylated interferon ALFA-2A and ribavirin in patients with chronic hepatitis C (CHC) genotype 1 infection","volume":"50","author":"Manns","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.25743","article-title":"Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study","volume":"56","author":"Manns","year":"2012","journal-title":"Hepatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0356|cit356","first-page":"332A","article-title":"Early viral response (EVR) rates in treatment - naive patients with chronic hepatitis C (CHC) genotype 1 infection treated with MK-7009, a novel NS3\/4a protease inhibitor, in combination with pegylated interferon alfa-2a and ribavirin for 28 days","volume":"50","author":"Manns","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0357|cit357","first-page":"361A","article-title":"Sustained viral response (SVR) rates in genotype 1 treatment-naive patients with chronic hepatitis C (CHC) infection treated with vaniprevir (MK-7009), A NS3\/4A protease inhibitor, in combination with pegylated interferon alfa-2a and ribavirin for 28 days","volume":"52","author":"Manns","year":"2010","journal-title":"Hepatology"},{"issue":"9941","key":"10.1002\/14651858.CD012143.pub3-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/S0016-5085(13)60541-7","article-title":"Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial","volume":"144","author":"Poordad","year":"2013","journal-title":"Gastroenterology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0360|cit360","first-page":"S342","article-title":"ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity in treatment naive GT1 chronic hepatitis C patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatology International"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0361|cit361","first-page":"S355","article-title":"12 week response-guided treatment with the NS5A inhibitor, GS-5885, the NS3 protease inhibitor, GS-9451, plus pegylated interferon\/ribavirin in treatment naive genotype 1 hepatitis C infected patients","volume":"58","author":"Marcellin","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jhep.2014.09.013","article-title":"Randomized study of danoprevir\/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon\/ribavirin","volume":"62","author":"Feld","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jhep.2015.03.042","article-title":"Randomized study of danoprevir\/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon\/ribavirin","volume":"63","author":"Song","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jhep.2014.09.013","article-title":"Randomized study of danoprevir\/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon\/ribavirin","volume":"62","author":"Feld","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jhep.2015.03.042","article-title":"Randomized study of danoprevir\/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon\/ribavirin","volume":"63","author":"Song","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0366|cit366","first-page":"167","article-title":"PROVE 1: subgroup analysis of a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C","volume":"3","author":"Everson","year":"2009","journal-title":"Hepatology International"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(08)60006-9","article-title":"PROVE1: results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C","volume":"48","author":"McHutchison","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"18","key":"10.1002\/14651858.CD012143.pub3-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0369|cit369","first-page":"167","article-title":"PROVE 1: subgroup analysis of a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C","volume":"3","author":"Everson","year":"2009","journal-title":"Hepatology International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1016\/S0168-8278(09)61046-1","article-title":"Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferonalfa-2A\/B and ribavirin therapy: SVR results of the PROVE3 study","volume":"50","author":"Manns","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"14","key":"10.1002\/14651858.CD012143.pub3-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchinson","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0372|cit372","first-page":"25","article-title":"Interim results of PROVE 3: a randomized, controlled, phase 2b study of telaprevir (TVR) with peginterferon-alfa-2a (P) and\/or ribavirin (R) in subjects with hepatitis C genotype 1 who failed to achieve an SVR with a prior course of PR therapy","volume":"3","author":"McHutchinson","year":"2009","journal-title":"Hepatology International"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0373|cit373","first-page":"334A","article-title":"PROVE3 final results and 1-year durability of SVR with telaprevir-based regimen in hepatitis C genotype 1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a\/b and ribavirin therapy","volume":"50","author":"McHutchison","year":"2009","journal-title":"Hepatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0374|cit374","first-page":"269A","article-title":"A phase 2b study of telaprevir with peginterferon-alfa-2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon-alfa-2a\/b and ribavirin therapy: PROVE3 interim results","volume":"48","author":"McHutchison","year":"2008","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0375|cit375","first-page":"S259","article-title":"Pilot study to determine the efficacy and safety of combining boceprevir with peginterferon alfa 2B and ribavirin in treatment naive patients with genotype 4 chronic hepatitis C infection","volume":"9","author":"Mostafa","year":"2015","journal-title":"Hepatology International"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0376|cit376","unstructured":"Muir A Poordad F Sheikh A Elkashab M Brennan R Ankoma-Sey V SVR4 results for the combination of ACH-3102 and Sovaprevir, with ribavirin, in patients with genotype 1 chronic hepatitis C infection 23rd Annual Conference of APASL, Brisbane, Australia 2014"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0377|cit377","first-page":"472A","article-title":"Once daily PSI-7977 plus PEG\/RBV in treatment naive patients with HCV GT1: robust end of treatment response rates are sustained posttreatment","volume":"54","author":"Lawitz","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"S544","DOI":"10.1016\/S0168-8278(11)61374-3","article-title":"Once daily PSI-7977 plus PEG-IFN\/RBV in HCV GT1: 98% rapid virologic response, complete early virologic response: the proton study","volume":"54","author":"Nelson","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1665-2681(19)31482-6","article-title":"Balapiravir plus peginterferon alfa-2a (40KD)\/ribavirin in a randomized trial of hepatitis C genotype 1 patients","volume":"11","author":"Nelson","year":"2012","journal-title":"Annals of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1665-2681(19)31482-6","article-title":"Balapiravir plus peginterferon alfa-2a (40KD)\/ribavirin in a randomized trial of hepatitis C genotype 1 patients","volume":"11","author":"Nelson","year":"2012","journal-title":"Annals of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1665-2681(19)31482-6","article-title":"Balapiravir plus peginterferon alfa-2a (40KD)\/ribavirin in a randomized trial of hepatitis C genotype 1 patients","volume":"11","author":"Nelson","year":"2012","journal-title":"Annals of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1665-2681(19)31482-6","article-title":"Balapiravir plus peginterferon alfa-2a (40KD)\/ribavirin in a randomized trial of hepatitis C genotype 1 patients","volume":"11","author":"Nelson","year":"2012","journal-title":"Annals of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1665-2681(19)31482-6","article-title":"Balapiravir plus peginterferon alfa-2a (40KD)\/ribavirin in a randomized trial of hepatitis C genotype 1 patients","volume":"11","author":"Nelson","year":"2012","journal-title":"Annals of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1665-2681(19)31482-6","article-title":"Balapiravir plus peginterferon alfa-2a (40KD)\/ribavirin in a randomized trial of hepatitis C genotype 1 patients","volume":"11","author":"Nelson","year":"2012","journal-title":"Annals of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(12)60026-9","article-title":"High SVR12 with 16 weeks of tegobuvir and GS-9256 with peginterferon-alfa 2A and ribavirin in treatment-na\u00efve genotype 1 HCV patients","volume":"56","author":"Nelson","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0386|cit386","first-page":"184","article-title":"MS-790052 is a first-in class potent Hepatitis C Virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study","volume":"4","author":"Nettles","year":"2010","journal-title":"Hepatology International"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0387|cit387","first-page":"1214A","article-title":"BMS-790052, a first-in class potent hepatitis C virus NS5A inhibitor, demonstrates multiple dose proof-of-concept in subjects with chronic GT1 HCV infection","volume":"52","author":"Nettles","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"Nettles","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0389|cit389","first-page":"1214A","article-title":"BMS-790052, a first-in class potent hepatitis C virus NS5A inhibitor, demonstrates multiple dose proof-of-concept in subjects with chronic GT1 HCV infection","volume":"52","author":"Nettles","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"Nettles","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0391|cit391","first-page":"1214A","article-title":"BMS-790052, a first-in class potent hepatitis C virus NS5A inhibitor, demonstrates multiple dose proof-of-concept in subjects with chronic GT1 HCV infection","volume":"52","author":"Nettles","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0392|cit392","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"Nettles","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0393|cit393","first-page":"1214A","article-title":"BMS-790052, a first-in class potent hepatitis C virus NS5A inhibitor, demonstrates multiple dose proof-of-concept in subjects with chronic GT1 HCV infection","volume":"52","author":"Nettles","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"Nettles","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0395|cit395","first-page":"1214A","article-title":"BMS-790052, a first-in class potent hepatitis C virus NS5A inhibitor, demonstrates multiple dose proof-of-concept in subjects with chronic GT1 HCV infection","volume":"52","author":"Nettles","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"Nettles","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0397|cit397","first-page":"1214A","article-title":"BMS-790052, a first-in class potent hepatitis C virus NS5A inhibitor, demonstrates multiple dose proof-of-concept in subjects with chronic GT1 HCV infection","volume":"52","author":"Nettles","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"Nettles","year":"2011","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0399|cit399","first-page":"S393","article-title":"All treated Japanese genotype 1 patients with IL28B TT allele achieved SVR by 4 weeks faldaprevir and 48 weeks PegIFN\/ ribavirin","volume":"7","author":"Nishiguchi","year":"2013","journal-title":"Hepatology International"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0400|cit400","first-page":"S372","article-title":"100% SVR in Japanese genotype 1 patients with IL28B TT allele treated with 4 weeks faldaprevir and 48 weeks PegIFN\/ribavirin","volume":"7","author":"Nishiguchi","year":"2013","journal-title":"Hepatology International"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/liv.12254","article-title":"Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection","volume":"34","author":"Nishiguchi","year":"2014","journal-title":"Liver International"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0402|cit402","first-page":"S393","article-title":"All treated Japanese genotype 1 patients with IL28B TT allele achieved SVR by 4 weeks faldaprevir and 48 weeks PegIFN\/ ribavirin","volume":"7","author":"Nishiguchi","year":"2013","journal-title":"Hepatology International"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0403|cit403","first-page":"S372","article-title":"100% SVR in Japanese genotype 1 patients with IL28B TT allele treated with 4 weeks faldaprevir and 48 weeks PegIFN\/ribavirin","volume":"7","author":"Nishiguchi","year":"2013","journal-title":"Hepatology International"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/liv.12254","article-title":"Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection","volume":"34","author":"Nishiguchi","year":"2014","journal-title":"Liver International"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3851\/IMP1894","article-title":"Rapid viral response of once-daily TMC435 plus pegylated interferon\/ribavirin in hepatitis C genotype-1 patients: a randomized trial","volume":"16","author":"Manns","year":"2011","journal-title":"Antiviral Therapy"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3851\/IMP1894","article-title":"Rapid viral response of once-daily TMC435 plus pegylated interferon\/ribavirin in hepatitis C genotype-1 patients: a randomized trial","volume":"16","author":"Manns","year":"2011","journal-title":"Antiviral Therapy"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3851\/IMP1894","article-title":"Rapid viral response of once-daily TMC435 plus pegylated interferon\/ribavirin in hepatitis C genotype-1 patients: a randomized trial","volume":"16","author":"Manns","year":"2011","journal-title":"Antiviral Therapy"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0408|cit408","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3851\/IMP1894","article-title":"Rapid viral response of once-daily TMC435 plus pegylated interferon\/ribavirin in hepatitis C genotype-1 patients: a randomized trial","volume":"16","author":"Manns","year":"2011","journal-title":"Antiviral Therapy"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0409|cit409","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3851\/IMP1894","article-title":"Rapid viral response of once-daily TMC435 plus pegylated interferon\/ribavirin in hepatitis C genotype-1 patients: a randomized trial","volume":"16","author":"Manns","year":"2011","journal-title":"Antiviral Therapy"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0410|cit410","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3851\/IMP1894","article-title":"Rapid viral response of once-daily TMC435 plus pegylated interferon\/ribavirin in hepatitis C genotype-1 patients: a randomized trial","volume":"16","author":"Manns","year":"2011","journal-title":"Antiviral Therapy"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0411|cit411","first-page":"184","article-title":"Safety, tolerability, pharmacokinetics and antiviral activity following single and multiple-dose administration of BMS-650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection","volume":"4","author":"Pasquinelli","year":"2010","journal-title":"Hepatology International"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0412|cit412","first-page":"411A","article-title":"Safety, tolerability, pharmacokinetics and antiviral activity following single-and multiple-dose administration of BMS-650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection","volume":"50","author":"Pasquinelli","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0413|cit413","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1128\/AAC.05854-11","article-title":"Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C","volume":"56","author":"Pasquinelli","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0414|cit414","first-page":"184","article-title":"Safety, tolerability, pharmacokinetics and antiviral activity following single and multiple-dose administration of BMS-650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection","volume":"4","author":"Pasquinelli","year":"2010","journal-title":"Hepatology International"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0415|cit415","first-page":"411A","article-title":"Safety, tolerability, pharmacokinetics and antiviral activity following single-and multiple-dose administration of BMS-650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection","volume":"50","author":"Pasquinelli","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0416|cit416","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1128\/AAC.05854-11","article-title":"Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C","volume":"56","author":"Pasquinelli","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0417|cit417","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.26624","article-title":"Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon\/ribavirin obviates a protease inhibitor","volume":"59","author":"Pearlman","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0418|cit418","doi-asserted-by":"crossref","first-page":"2423-4","DOI":"10.1002\/hep.26771","article-title":"Re: Pearlman and Ehleben - hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon\/ribavirin obviates a protease inhibitor","volume":"59","author":"Wang","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0419|cit419","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1053\/j.gastro.2014.12.027","article-title":"The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis","volume":"148","author":"Pearlman","year":"2015","journal-title":"Gastroenterology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0420|cit420","first-page":"531A","article-title":"Safety and antiviral activity of MK-5172, a next generation HCV NS3\/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 HCV infected patients","volume":"54","author":"Petry","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0421|cit421","doi-asserted-by":"crossref","first-page":"S371","DOI":"10.1016\/S0168-8278(08)60995-2","article-title":"High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2A (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa-2A and ribavirin","volume":"48","author":"Nelson","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0422|cit422","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hep.22357","article-title":"R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin","volume":"48","author":"Pockros","year":"2008","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0423|cit423","doi-asserted-by":"crossref","first-page":"S371","DOI":"10.1016\/S0168-8278(08)60995-2","article-title":"High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2A (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa-2A and ribavirin","volume":"48","author":"Nelson","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0424|cit424","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hep.22357","article-title":"R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin","volume":"48","author":"Pockros","year":"2008","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0425|cit425","doi-asserted-by":"crossref","first-page":"S371","DOI":"10.1016\/S0168-8278(08)60995-2","article-title":"High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2A (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa-2A and ribavirin","volume":"48","author":"Nelson","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0426|cit426","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hep.22357","article-title":"R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin","volume":"48","author":"Pockros","year":"2008","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0427|cit427","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(09)60015-5","article-title":"A phase 2, randomized study of HCV-796 in combination with pegylated-interferon (PEG) plus ribavirin (RBV) versus peg plus RBV in hepatitis C virus genotype-1 infection","volume":"50","author":"Pockros","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD012143.pub3-BIB0428|cit428","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1473-3099(12)70138-X","article-title":"Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial","volume":"12","author":"Pol","year":"2012","journal-title":"Lancet Infectious Diseases"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0429|cit429","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0168-8278(13)60070-7","article-title":"Antiviral efficacy of the NS3 protease inhibitor, GS-9451, non-nucleoside NS5b inhibitor, tegobuvir, and pegylated interferon plus ribavirin in treatment-naive genotype 1 hepatitis C infected patients","volume":"58","author":"Pol","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0430|cit430","first-page":"866A","article-title":"Efficacy and safety of valopicitabine in combination with pegylated interferon (Peg IFN) and ribavirin (RBV) in patients with chronic hepatitis C","volume":"46","author":"Poordad","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0431|cit431","first-page":"261","article-title":"Frequencies of resistance-associated amino acid variants (RAV) following treatment with boceprevir (BOC) plus peginterferon alfa-2b and ribavirin (P\/R)","volume":"5","author":"Albrecht","year":"2011","journal-title":"Hepatology International"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0432|cit432","first-page":"199","article-title":"Frequencies of resistance-associated amino acid variants following combination treatment with boceprevir (BOC) plus Pegintron (peglnterferon alfa-2b) and ribavirin (P\/R) in patients with chronic hepatitis C (CHC), genotype 1 (G1)","volume":"10","author":"Barnard","year":"2011","journal-title":"Journal of the International Association of Physicians in AIDS Care"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0433|cit433","first-page":"881A","article-title":"Response-guided therapy (RGT) with boceprevir (BOC) + peginterferon alfa-2b\/ribavirin (P\/R) for treatment-naive patients with hepatitis C virus (HCV) genotype (G) 1 was similar to a 48-wk fixed-duration regimen with BOC + P\/R in SPRINT-2","volume":"52","author":"Bronowicki","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0434|cit434","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/hep.24648","article-title":"Boceprevir (Victrelis) for HCV: V is for victory and very complex","volume":"54","author":"Charlton","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0435|cit435","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1478-3231.2011.02725.x","article-title":"Phase III results of boceprevir in treatment naive patients with chronic hepatitis C genotype 1","volume":"32","author":"Manns","year":"2012","journal-title":"Liver International"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0436|cit436","first-page":"813A","article-title":"Safety benefits of response-guided therapy with boceprevir (BOC) plus peginterferon alfa-2B\/ribavirin (PR) in previously untreated patients with HCV genotype 1 infection","volume":"54","author":"Manns","year":"2011","journal-title":"Hepatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0437|cit437","first-page":"822A","article-title":"Treatment-naive black patients treated with boceprevir combined with peginterferon alfa-2b + ribavirin: results from HCV sprint-2","volume":"54","author":"McCone","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0438|cit438","first-page":"402A","article-title":"Boceprevir (BOC) combined with peginterferon alfa-2b\/ribavirin (P\/R) for treatment-naive patients with hepatitis C virus (HCV) genotype (G) 1: SPRINT-2 final results","volume":"52","author":"Poordad","year":"2010","journal-title":"Hepatology"},{"issue":"13","key":"10.1002\/14651858.CD012143.pub3-BIB0439|cit439","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0440|cit440","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S0168-8278(11)60468-6","article-title":"Predictors of sustained virologic response among treatment-naive patients with hepatitis C virus genotype 1 when treated with boceprevir (BOC) plus peginterferon alfa-2B\/ribavirin (PR)","volume":"54","author":"Reddy","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0441|cit441","first-page":"197","article-title":"Boceprevir combined with peginterferon alfa-2b\/ribavirin for previous treatment failure patients with hepatitis C virus genotype 1: RESPOND-2 final results","volume":"10","author":"Sulkowski","year":"2011","journal-title":"Journal of the International Association of Physicians in AIDS Care"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0442|cit442","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/hep.26096","article-title":"Anemia during treatment with peginterferon alfa-2b\/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0443|cit443","first-page":"881A","article-title":"Response-guided therapy (RGT) with boceprevir (BOC) + peginterferon alfa-2b\/ribavirin (P\/R) for treatment-naive patients with hepatitis C virus (HCV) genotype (G) 1 was similar to a 48-wk fixed-duration regimen with BOC + P\/R in SPRINT-2","volume":"52","author":"Bronowicki","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0444|cit444","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/hep.24648","article-title":"Boceprevir (Victrelis) for HCV: V is for victory and very complex","volume":"54","author":"Charlton","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0445|cit445","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1478-3231.2011.02725.x","article-title":"Phase III results of boceprevir in treatment naive patients with chronic hepatitis C genotype 1","volume":"32","author":"Manns","year":"2012","journal-title":"Liver International"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0446|cit446","first-page":"813A","article-title":"Safety benefits of response-guided therapy with boceprevir (BOC) plus peginterferon alfa-2B\/ribavirin (PR) in previously untreated patients with HCV genotype 1 infection","volume":"54","author":"Manns","year":"2011","journal-title":"Hepatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0447|cit447","first-page":"822A","article-title":"Treatment-naive black patients treated with boceprevir combined with peginterferon alfa-2b + ribavirin: results from HCV sprint-2","volume":"54","author":"McCone","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0448|cit448","first-page":"402A","article-title":"Boceprevir (BOC) combined with peginterferon alfa-2b\/ribavirin (P\/R) for treatment-naive patients with hepatitis C virus (HCV) genotype (G) 1: SPRINT-2 final results","volume":"52","author":"Poordad","year":"2010","journal-title":"Hepatology"},{"issue":"13","key":"10.1002\/14651858.CD012143.pub3-BIB0449|cit449","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0450|cit450","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S0168-8278(11)60468-6","article-title":"Predictors of sustained virologic response among treatment-naive patients with hepatitis C virus genotype 1 when treated with boceprevir (BOC) plus peginterferon alfa-2B\/ribavirin (PR)","volume":"54","author":"Reddy","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0451|cit451","first-page":"197","article-title":"Boceprevir combined with peginterferon alfa-2b\/ribavirin for previous treatment failure patients with hepatitis C virus genotype 1: RESPOND-2 final results","volume":"10","author":"Sulkowski","year":"2011","journal-title":"Journal of the International Association of Physicians in AIDS Care"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0452|cit452","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/hep.26096","article-title":"Anemia during treatment with peginterferon alfa-2b\/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"issue":"20","key":"10.1002\/14651858.CD012143.pub3-BIB0453|cit453","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0454|cit454","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2013.12.006","article-title":"Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C)","volume":"60","author":"Younossi","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0455|cit455","first-page":"862A","article-title":"Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy","volume":"46","author":"Reddy","year":"2007","journal-title":"Hepatology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0456|cit456","first-page":"A697","article-title":"Initial results of a phase 1b, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor","volume":"128","author":"Reesink","year":"2005","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0457|cit457","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2006.07.013","article-title":"Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study","volume":"131","author":"Reesink","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0458|cit458","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/hep.20612","article-title":"Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C","volume":"41","author":"Reiser","year":"2005","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0459|cit459","first-page":"1160A","article-title":"Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with peg-ifn and ribavirin: subanalysis by race\/ethnicity, weight and HCV genotype","volume":"48","author":"Rodriguez-Torres","year":"2008","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0460|cit460","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0168-8278(10)60033-5","article-title":"Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment-naive genotype 1 HCV infected patients","volume":"52","author":"Rodriguez-Torres","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0461|cit461","first-page":"535A","article-title":"Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7-days of oral therapy in naive genotype-1 chronic HCV patients","volume":"54","author":"Rodriguez-Torres","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0462|cit462","doi-asserted-by":"crossref","first-page":"S488","DOI":"10.1016\/S0168-8278(11)61237-3","article-title":"PSI-352938, a novel purine nucleotide analog, exhibits potent antiviral activity and no evidence of resistance in patients with HCV genotype 1 over 7 days","volume":"54","author":"Rodriguez-Torres","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0463|cit463","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2012.11.018","article-title":"Sofosbuvir (GS-7977) plus peginterferon\/ribavirin in treatment-na\u00efve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial","volume":"58","author":"Rodriguez-Torres","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0464|cit464","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.cgh.2013.09.067","article-title":"Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis","volume":"12","author":"Rodriguez-Torres","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0465|cit465","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.cgh.2013.09.067","article-title":"Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis","volume":"12","author":"Rodriguez-Torres","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0466|cit466","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.cgh.2013.09.067","article-title":"Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis","volume":"12","author":"Rodriguez-Torres","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0467|cit467","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.cgh.2013.09.067","article-title":"Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis","volume":"12","author":"Rodriguez-Torres","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0468|cit468","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S1665-2681(19)30843-9","article-title":"A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV","volume":"13","author":"Rodriguez-Torres","year":"2014","journal-title":"Annals of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0469|cit469","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S1665-2681(19)30843-9","article-title":"A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV","volume":"13","author":"Rodriguez-Torres","year":"2014","journal-title":"Annals of Hepatology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0470|cit470","doi-asserted-by":"crossref","first-page":"S682","DOI":"10.1016\/S0168-8278(15)31104-1","article-title":"The pan-genotypic NS3\/4A protease inhibitor GS-9857 demonstrates potent antiviral activity in patients infected with HCV genotype 1, 2, 3 or 4 in a 3-day monotherapy study","volume":"62","author":"Rodriguez-Torres","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0471|cit471","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1053\/j.gastro.2007.01.041","article-title":"SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0472|cit472","first-page":"1040A","article-title":"Clonal analysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders sequentially treated with boceprevir (SCH503034) and\/or pegylated interferon alfa-2b (PEG-IFN \u03b1-2b)","volume":"50","author":"Vermehren","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0473|cit473","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0168-8278(08)60106-3","article-title":"Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness","volume":"48","author":"Schiff","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0474|cit474","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2013.02.018","article-title":"Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2\/3","volume":"59","author":"Silva","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0475|cit475","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2013.02.018","article-title":"Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2\/3","volume":"59","author":"Silva","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0476|cit476","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2013.02.018","article-title":"Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2\/3","volume":"59","author":"Silva","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0477|cit477","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1128\/AAC.02579-13","article-title":"Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection","volume":"58","author":"Sims","year":"2014","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0478|cit478","first-page":"S","article-title":"Faldaprevir plus pegylated interferon\/ribavirin did not increase anaemia compared with pegylated interferon\/ribavirin in HCV genotype-1, treatment-naive patients: pooled analysis of phase III studies","volume":"146","author":"Asselah","year":"2014","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0479|cit479","doi-asserted-by":"crossref","first-page":"S975","DOI":"10.1016\/S0016-5085(14)63544-7","article-title":"Virological response in treatment-naive patients with chronic HCV genotype-1 infection receiving faldaprevir plus pegylated interferon alpha-2a and ribavirin is unaffected by ribavirin dose reduction","volume":"146","author":"Asselah","year":"2014","journal-title":"Gastroenterology"},{"issue":"1 Suppl S","key":"10.1002\/14651858.CD012143.pub3-BIB0480|cit480","first-page":"S497","article-title":"NS3 Q80K did not impact efficacy or treatment-emergent resistance patterns in HCV genotype 1-infected patients receiving faldaprevir + peginterferon\/ribavirin in three phase III trials","volume":"60","author":"Berger","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0481|cit481","first-page":"157","article-title":"Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from STARTVerso1, a randomised, double-blind, placebo-controlled phase III trial","volume":"28","author":"Ferenci","year":"2013","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0482|cit482","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jhep.2014.12.024","article-title":"STARTVerso1: a randomized trial of faldaprevir plus pegylated interferon\/ribavirin for chronic HCV genotype-1 infection","volume":"62","author":"Ferenci","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0483|cit483","doi-asserted-by":"crossref","first-page":"S452","DOI":"10.1016\/S0168-8278(14)61281-2","article-title":"Early stopping rules for faldaprevir plus pegylated interferon alpha-2a and ribavirin in treatment-naive patients: exploratory study of pooled data from phase III trials","volume":"60","author":"Ferenci","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0484|cit484","doi-asserted-by":"crossref","first-page":"S454","DOI":"10.1016\/S0168-8278(14)61285-X","article-title":"Pharmacokinetic-response analysis of faldaprevir in treatment-naive patients with chronic HCV genotype-1 infection: a pooled analysis of two phase III trials","volume":"60","author":"Foster","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0485|cit485","first-page":"734A","article-title":"A pooled analysis of two randomized, double-blind placebo-controlled phase III trials (STARTVerso1 & 2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection","volume":"58","author":"Jensen","year":"2013","journal-title":"Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0486|cit486","doi-asserted-by":"crossref","first-page":"S974","DOI":"10.1016\/S0016-5085(14)63540-X","article-title":"Faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection: a pooled analysis of two randomized, double-blind placebo-controlled phase III trials (STARTVerso 1 & 2)","volume":"146","author":"Jensen","year":"2014","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0487|cit487","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.14309\/00000434-201310001-00487","article-title":"Faldaprevir plus pegylated interferon alfa-2a and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from STARTVerso1: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"108","author":"Moreno","year":"2013","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0488|cit488","first-page":"751A","article-title":"Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection: a pooled analysis of STARTVerso1 and 2","volume":"58","author":"Yoshida","year":"2013","journal-title":"Hepatology"},{"issue":"1 Suppl S","key":"10.1002\/14651858.CD012143.pub3-BIB0489|cit489","doi-asserted-by":"crossref","first-page":"S451","DOI":"10.1016\/S0168-8278(14)61278-2","article-title":"No effect of faldaprevir on renal function in treatment-naive patients with chronic HCV genotype-1 infection: pooled data from two phase III trials","volume":"60","author":"Zeuzem","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0490|cit490","first-page":"S","article-title":"Faldaprevir plus pegylated interferon\/ribavirin did not increase anaemia compared with pegylated interferon\/ribavirin in HCV genotype-1, treatment-naive patients: pooled analysis of phase III studies","volume":"146","author":"Asselah","year":"2014","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0491|cit491","doi-asserted-by":"crossref","first-page":"S975","DOI":"10.1016\/S0016-5085(14)63544-7","article-title":"Virological response in treatment-naive patients with chronic HCV genotype-1 infection receiving faldaprevir plus pegylated interferon alpha-2a and ribavirin is unaffected by ribavirin dose reduction","volume":"146","author":"Asselah","year":"2014","journal-title":"Gastroenterology"},{"issue":"1 Suppl S","key":"10.1002\/14651858.CD012143.pub3-BIB0492|cit492","first-page":"S497","article-title":"NS3 Q80K did not impact efficacy or treatment-emergent resistance patterns in HCV genotype 1-infected patients receiving faldaprevir + peginterferon\/ribavirin in three phase III trials","volume":"60","author":"Berger","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0493|cit493","first-page":"157","article-title":"Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from STARTVerso1, a randomised, double-blind, placebo-controlled phase III trial","volume":"28","author":"Ferenci","year":"2013","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0494|cit494","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jhep.2014.12.024","article-title":"STARTVerso1: a randomized trial of faldaprevir plus pegylated interferon\/ribavirin for chronic HCV genotype-1 infection","volume":"62","author":"Ferenci","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0495|cit495","doi-asserted-by":"crossref","first-page":"S452","DOI":"10.1016\/S0168-8278(14)61281-2","article-title":"Early stopping rules for faldaprevir plus pegylated interferon alpha-2a and ribavirin in treatment-naive patients: exploratory study of pooled data from phase III trials","volume":"60","author":"Ferenci","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0496|cit496","doi-asserted-by":"crossref","first-page":"S454","DOI":"10.1016\/S0168-8278(14)61285-X","article-title":"Pharmacokinetic-response analysis of faldaprevir in treatment-naive patients with chronic HCV genotype-1 infection: a pooled analysis of two phase III trials","volume":"60","author":"Foster","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0497|cit497","first-page":"734A","article-title":"A pooled analysis of two randomized, double-blind placebo-controlled phase III trials (STARTVerso1 & 2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection","volume":"58","author":"Jensen","year":"2013","journal-title":"Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0498|cit498","doi-asserted-by":"crossref","first-page":"S974","DOI":"10.1016\/S0016-5085(14)63540-X","article-title":"Faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection: a pooled analysis of two randomized, double-blind placebo-controlled phase III trials (STARTVerso 1 & 2)","volume":"146","author":"Jensen","year":"2014","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0499|cit499","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.14309\/00000434-201310001-00487","article-title":"Faldaprevir plus pegylated interferon alfa-2a and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from STARTVerso1: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"108","author":"Moreno","year":"2013","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0500|cit500","first-page":"751A","article-title":"Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection: a pooled analysis of STARTVerso1 and 2","volume":"58","author":"Yoshida","year":"2013","journal-title":"Hepatology"},{"issue":"1 Suppl S","key":"10.1002\/14651858.CD012143.pub3-BIB0501|cit501","doi-asserted-by":"crossref","first-page":"S451","DOI":"10.1016\/S0168-8278(14)61278-2","article-title":"No effect of faldaprevir on renal function in treatment-naive patients with chronic HCV genotype-1 infection: pooled data from two phase III trials","volume":"60","author":"Zeuzem","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"5 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0502|cit502","first-page":"S","article-title":"Faldaprevir plus pegylated interferon\/ribavirin did not increase anaemia compared with pegylated interferon\/ribavirin in HCV genotype-1, treatment-naive patients: pooled analysis of phase III studies","volume":"146","author":"Asselah","year":"2014","journal-title":"Gastroenterology"},{"issue":"5 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0503|cit503","doi-asserted-by":"crossref","first-page":"S975","DOI":"10.1016\/S0016-5085(14)63544-7","article-title":"Virological response in treatment-naive patients with chronic HCV genotype-1 infection receiving faldaprevir plus pegylated interferon alpha-2a and ribavirin is unaffected by ribavirin dose reduction","volume":"146","author":"Asselah","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0504|cit504","first-page":"S497","article-title":"NS3 Q80K did not impact efficacy or treatment-emergent resistance patterns in HCV genotype 1-infected patients receiving faldaprevir + peginterferon\/ribavirin in three phase III trials","volume":"60","author":"Berger","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"1 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0505|cit505","doi-asserted-by":"crossref","first-page":"S452","DOI":"10.1016\/S0168-8278(14)61281-2","article-title":"Early stopping rules for faldaprevir plus pegylated interferon alpha-2a and ribavirin in treatment-naive patients: exploratory study of pooled data from phase III trials","volume":"60","author":"Ferenci","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"1 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0506|cit506","doi-asserted-by":"crossref","first-page":"S454","DOI":"10.1016\/S0168-8278(14)61285-X","article-title":"Pharmacokinetic-response analysis of faldaprevir in treatment-naive patients with chronic HCV genotype-1 infection: a pooled analysis of two phase III trials","volume":"60","author":"Foster","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0507|cit507","first-page":"734A","article-title":"A pooled analysis of two randomized, double-blind placebo-controlled phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection","volume":"58","author":"Jensen","year":"2013","journal-title":"Hepatology"},{"issue":"5 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0508|cit508","doi-asserted-by":"crossref","first-page":"S974","DOI":"10.1016\/S0016-5085(14)63540-X","article-title":"Faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection: a pooled analysis of two randomized, double-blind placebo-controlled phase iii trials (STARTVerso1&2)","volume":"146","author":"Jensen","year":"2014","journal-title":"Gastroenterology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0509|cit509","first-page":"751A","article-title":"Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection: a pooled analysis of STARTVerso1 and 2","volume":"58","author":"Yoshida","year":"2013","journal-title":"Hepatology"},{"issue":"1 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0510|cit510","doi-asserted-by":"crossref","first-page":"S451","DOI":"10.1016\/S0168-8278(14)61278-2","article-title":"No effect of faldaprevir on renal function in treatment-naive patients with chronic HCV genotype-1 infection: pooled data from two phase III trials","volume":"60","author":"Zeuzem","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"5 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0511|cit511","first-page":"S","article-title":"Faldaprevir plus pegylated interferon\/ribavirin did not increase anaemia compared with pegylated interferon\/ribavirin in HCV genotype-1, treatment-naive patients: pooled analysis of phase III studies","volume":"146","author":"Asselah","year":"2014","journal-title":"Gastroenterology"},{"issue":"5 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0512|cit512","doi-asserted-by":"crossref","first-page":"S975","DOI":"10.1016\/S0016-5085(14)63544-7","article-title":"Virological response in treatment-naive patients with chronic HCV genotype-1 infection receiving faldaprevir plus pegylated interferon alpha-2a and ribavirin is unaffected by ribavirin dose reduction","volume":"146","author":"Asselah","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0513|cit513","first-page":"S497","article-title":"NS3 Q80K did not impact efficacy or treatment-emergent resistance patterns in HCV genotype 1-infected patients receiving faldaprevir + peginterferon\/ribavirin in three phase III trials","volume":"60","author":"Berger","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"1 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0514|cit514","doi-asserted-by":"crossref","first-page":"S452","DOI":"10.1016\/S0168-8278(14)61281-2","article-title":"Early stopping rules for faldaprevir plus pegylated interferon alpha-2a and ribavirin in treatment-naive patients: exploratory study of pooled data from phase III trials","volume":"60","author":"Ferenci","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"1 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0515|cit515","doi-asserted-by":"crossref","first-page":"S454","DOI":"10.1016\/S0168-8278(14)61285-X","article-title":"Pharmacokinetic-response analysis of faldaprevir in treatment-naive patients with chronic HCV genotype-1 infection: a pooled analysis of two phase III trials","volume":"60","author":"Foster","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0516|cit516","first-page":"734A","article-title":"A pooled analysis of two randomized, double-blind placebo-controlled phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection","volume":"58","author":"Jensen","year":"2013","journal-title":"Hepatology"},{"issue":"5 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0517|cit517","doi-asserted-by":"crossref","first-page":"S974","DOI":"10.1016\/S0016-5085(14)63540-X","article-title":"Faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection: a pooled analysis of two randomized, double-blind placebo-controlled phase iii trials (STARTVerso1&2)","volume":"146","author":"Jensen","year":"2014","journal-title":"Gastroenterology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0518|cit518","first-page":"751A","article-title":"Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection: a pooled analysis of STARTVerso1 and 2","volume":"58","author":"Yoshida","year":"2013","journal-title":"Hepatology"},{"issue":"1 (Suppl 1)","key":"10.1002\/14651858.CD012143.pub3-BIB0519|cit519","doi-asserted-by":"crossref","first-page":"S451","DOI":"10.1016\/S0168-8278(14)61278-2","article-title":"No effect of faldaprevir on renal function in treatment-naive patients with chronic HCV genotype-1 infection: pooled data from two phase III trials","volume":"60","author":"Zeuzem","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"1 Suppl S","key":"10.1002\/14651858.CD012143.pub3-BIB0520|cit520","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/S0168-8278(14)61292-7","article-title":"Pharmacokinetic-response analysis of faldaprevir in patients with chronic HCV genotype-1 infection with prior relapse","volume":"60","author":"Asselah","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"1 Suppl S","key":"10.1002\/14651858.CD012143.pub3-BIB0521|cit521","first-page":"S497","article-title":"NS3 Q80K did not impact efficacy or treatment-emergent resistance patterns in HCV genotype 1-infected patients receiving faldaprevir+peginterferon\/ribavirin in three phase III trials","volume":"60","author":"Berger","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0522|cit522","first-page":"742A","article-title":"STARTVerso3: a randomized, double-blind, placebo-controlled phase III trial of faldaprevir in combination with pegylated interferon a lf a-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection","volume":"48","author":"Jacobson","year":"2013","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0523|cit523","first-page":"S213","article-title":"STARTVerso3: a randomized, double-blind, placebo controlled phase III trial of faldaprevir in combination with pegylated interferon alpha-2a and ribavirin in treatment experienced patients with chronic hepatitis C genotype-1 infection","volume":"8","author":"Jacobson","year":"2014","journal-title":"Hepatology International"},{"issue":"1 Suppl S","key":"10.1002\/14651858.CD012143.pub3-BIB0524|cit524","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/S0168-8278(14)61292-7","article-title":"Pharmacokinetic-response analysis of faldaprevir in patients with chronic HCV genotype-1 infection with prior relapse","volume":"60","author":"Asselah","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"1 Suppl S","key":"10.1002\/14651858.CD012143.pub3-BIB0525|cit525","first-page":"S497","article-title":"NS3 Q80K did not impact efficacy or treatment-emergent resistance patterns in HCV genotype 1-infected patients receiving faldaprevir+peginterferon\/ribavirin in three phase III trials","volume":"60","author":"Berger","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0526|cit526","first-page":"742A","article-title":"STARTVerso3: a randomized, double-blind, placebo-controlled phase III trial of faldaprevir in combination with pegylated interferon a lf a-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection","volume":"48","author":"Jacobson","year":"2013","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0527|cit527","first-page":"S213","article-title":"STARTVerso3: a randomized, double-blind, placebo controlled phase III trial of faldaprevir in combination with pegylated interferon alpha-2a and ribavirin in treatment experienced patients with chronic hepatitis C genotype-1 infection","volume":"8","author":"Jacobson","year":"2014","journal-title":"Hepatology International"},{"issue":"1 Suppl S","key":"10.1002\/14651858.CD012143.pub3-BIB0528|cit528","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/S0168-8278(14)61292-7","article-title":"Pharmacokinetic-response analysis of faldaprevir in patients with chronic HCV genotype-1 infection with prior relapse","volume":"60","author":"Asselah","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"1 Suppl S","key":"10.1002\/14651858.CD012143.pub3-BIB0529|cit529","first-page":"S497","article-title":"NS3 Q80K did not impact efficacy or treatment-emergent resistance patterns in HCV genotype 1-infected patients receiving faldaprevir+peginterferon\/ribavirin in three phase III trials","volume":"60","author":"Berger","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0530|cit530","first-page":"742A","article-title":"STARTVerso3: a randomized, double-blind, placebo-controlled phase III trial of faldaprevir in combination with pegylated interferon a lf a-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection","volume":"48","author":"Jacobson","year":"2013","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0531|cit531","first-page":"S213","article-title":"STARTVerso3: a randomized, double-blind, placebo controlled phase III trial of faldaprevir in combination with pegylated interferon alpha-2a and ribavirin in treatment experienced patients with chronic hepatitis C genotype-1 infection","volume":"8","author":"Jacobson","year":"2014","journal-title":"Hepatology International"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0532|cit532","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/QAD.0000000000000579","article-title":"Faldaprevir and pegylated interferon alpha-2a\/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV","volume":"29","author":"Dieterich","year":"2015","journal-title":"AIDS"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0533|cit533","first-page":"1431A","article-title":"Telaprevir combination with peginterferon alfa-2A\/ribavirin in HCV\/HIV coinfected patients: 24-week treatment interim analysis","volume":"54","author":"Sherman","year":"2011","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0534|cit534","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","article-title":"Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial","volume":"159","author":"Sulkowski","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0535|cit535","first-page":"219A","article-title":"Telaprevir in combination with peginterferon alfa-2a\/ribavirin in HCV\/HIV co-infected patients: SVR24 final study results","volume":"56","author":"Sulkowski","year":"2012","journal-title":"Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0536|cit536","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(13)70149-X","article-title":"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial","volume":"13","author":"Sulkowski","year":"2013","journal-title":"Lancet Infectious Diseases"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0537|cit537","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/S0168-8278(12)61197-0","article-title":"Characterization of HCV NS3 variants that emerged during virologic breakthrough and relapse from BI 201335 phase II SILEN-C2 study in PEGIFN\/RBV treatment-experienced patients","volume":"56","author":"Kukolj","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0538|cit538","first-page":"473A","article-title":"Treatment with the second generation HCV protease inhibitor BI201335 results in high and consistent SVR rates - results from silen-C1 in treatment-naive patients across different baseline factors","volume":"54","author":"Sulkowski","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0539|cit539","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/hep.26276","article-title":"Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-na\u00efve patients with chronic genotype 1 HCV: SILEN-C1 trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0540|cit540","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0168-8278(11)60062-7","article-title":"Silen-C1: sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P\/R) in treatment-naive patients with chronic genotype 1 HCV Infection","volume":"54","author":"Sulkowski","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0541|cit541","doi-asserted-by":"crossref","first-page":"S480","DOI":"10.1016\/S0168-8278(12)61222-7","article-title":"ABT-267 combined with pegylated interferon alpha- 2a\/ribavirin in genotype 1 (GT1) HCV-infected treatment naive subjects: 12 week antiviral and safety analysis","volume":"56","author":"Sullivan","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0542|cit542","first-page":"1530A","article-title":"High sustained viral response with a HCV p7 inhibitor, BIT225: antiviral activity and tolerability of BIT225 plus pegylated interferon alfa 2b and weight-based ribavirin for 28 days in HCV treatment-naive patients","volume":"56","author":"Tanwandee","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0543|cit543","first-page":"S473","article-title":"Characterization of viral escape in HCV genotype 1-infected patients treated with BMS-791325 and pegylated interferon-ALFA and ribavirin","volume":"56","author":"McPhee","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0544|cit544","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.1016\/S0168-8278(12)61175-1","article-title":"A phase 2A study of BMS-791325, an NS5B polymerase inhibitor, with peginterferon alfa-2A and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection","volume":"56","author":"Tatum","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD012143.pub3-BIB0545|cit545","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jvh.12372","article-title":"A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon\/ribavirin for HCV genotype 1","volume":"22","author":"Tatum","year":"2015","journal-title":"Journal of Viral Hepatitis"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0546|cit546","first-page":"759A","article-title":"Safety and efficacy of BMS-791325, a non-nucleoside NS5B polymerase inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive patients infected with hepatitis C virus genotype 1","volume":"58","author":"Tatum","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0547|cit547","first-page":"S473","article-title":"Characterization of viral escape in HCV genotype 1-infected patients treated with BMS-791325 and pegylated interferon-ALFA and ribavirin","volume":"56","author":"McPhee","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0548|cit548","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.1016\/S0168-8278(12)61175-1","article-title":"A phase 2A study of BMS-791325, an NS5B polymerase inhibitor, with peginterferon alfa-2A and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection","volume":"56","author":"Tatum","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD012143.pub3-BIB0549|cit549","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jvh.12372","article-title":"A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon\/ribavirin for HCV genotype 1","volume":"22","author":"Tatum","year":"2015","journal-title":"Journal of Viral Hepatitis"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0550|cit550","first-page":"759A","article-title":"Safety and efficacy of BMS-791325, a non-nucleoside NS5B polymerase inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive patients infected with hepatitis C virus genotype 1","volume":"58","author":"Tatum","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0551|cit551","first-page":"1437A","article-title":"Once daily narlaprevir (NVR; SCH 900518) and ritonavir (RTV) in combination with peginterferon alfa-2B\/ribavirin (PR) for 12 weeks plus 12 weeks pr in treatment-na\u00efve patients with HCV genotype 1 (G1): SVR results from next-1, a phase 2 study","volume":"54","author":"Vierling","year":"2011","journal-title":"Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0552|cit552","first-page":"815A","article-title":"Phase 1 evaluation of antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with different pegylated interferons in treatment-naive patients with chronic HCV","volume":"46","author":"Villano","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0553|cit553","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jhep.2014.01.003","article-title":"A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4","volume":"60","author":"Vince","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0554|cit554","first-page":"553A","article-title":"The effect of host il28b genotype and mericitabine (MCB; RG7128) dose on early viral kinetics following administration of MCB plus pegifn alpha-2a plus ribavirin (P\/R) in patients with chronic hepatitis C (CHC)","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0555|cit555","first-page":"360A","article-title":"High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1\/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)\/RBV: planned week 12 interim analysis from the PROPEL study","volume":"52","author":"Jensen","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0556|cit556","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1016\/S0168-8278(12)61225-2","article-title":"Efficacy and safety of mericitabine (MCB) in combination with Peg-Ifn alpha-2A\/RBV in G1\/4 treatment naive HCV patients: final analysis from the PROPEL study","volume":"56","author":"Wedemeyer","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0557|cit557","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep.26274","article-title":"PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a\/ribavirin therapy in treatment-naive HCV genotype 1\/4 patients","volume":"58","author":"Wedemeyer","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0558|cit558","first-page":"400A","article-title":"GSK2336805 HCV NS5A inhibitor demonstrates potent antiviral activity in chronic genotype 1 infection; results from a first time in human (FTIH) single and repeat dose study","volume":"54","author":"Spreen","year":"2011","journal-title":"Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD012143.pub3-BIB0559|cit559","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1128\/AAC.00910-13","article-title":"Safety, tolerability, pharmacokinetics, and antiviral activity OFGSK2336805, an inhibitor of hepatitis C virus (HCV) NA5A, in healthy subjects and subjects chronically infected with HCV genotype 1","volume":"57","author":"Wilfret","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0560|cit560","doi-asserted-by":"crossref","first-page":"S591","DOI":"10.1016\/S0168-8278(15)30916-8","article-title":"The impact of ledipasvir (LDV)\/sofosbuvir (SOF) combination on health-related quality of life (HRQL) and patient-reported outcomes (PROS) in cirrhotic patients with chronic hepatitis C (CH-C): the SIRIUS study","volume":"62","author":"Younossi","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0561|cit561","first-page":"375A","article-title":"Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon\/ribavirin treatment failure: post-hoc analysis of the phase III REALIZE study","volume":"54","author":"Berg","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0562|cit562","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/hep.25962","article-title":"Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial","volume":"56","author":"Meyer","year":"2012","journal-title":"Hepatology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0563|cit563","doi-asserted-by":"crossref","first-page":"S456","DOI":"10.1016\/S0168-8278(14)61287-3","article-title":"Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive European patients in the QUEST-1 and QUEST-2 phase III trials","volume":"60","author":"Foster","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0564|cit564","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(11)60008-1","article-title":"Subanalyses of the telaprevir lead-in arm in the REALIZE study: response at week 4 is not a substitute for prior null response categorization","volume":"54","author":"Foster","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0565|cit565","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jhep.2012.11.013","article-title":"Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure","volume":"58","author":"Foster","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0566|cit566","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(11)60015-9","article-title":"Similar SVR rates in IL28B CC, CT OR TT prior relapser, partial- or null-responder patients treated with telaprevir\/peginterferon\/ribavirin: retrospective analysis of the REALIZE study","volume":"54","author":"Pol","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0567|cit567","first-page":"374A","article-title":"Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon\/ribavirin treatment failure: subanalysis of the REALIZE phase III study","volume":"54","author":"Pol","year":"2011","journal-title":"Hepatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0568|cit568","first-page":"1007A","article-title":"Impact of anemia and ribavirin dose reduction on SVR to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon\/ribavirin treatment failure in the phase III REALIZE study","volume":"54","author":"Roberts","year":"2011","journal-title":"Hepatology"},{"issue":"1 Suppl S","key":"10.1002\/14651858.CD012143.pub3-BIB0569|cit569","doi-asserted-by":"crossref","first-page":"S490","DOI":"10.1016\/S0168-8278(14)61366-0","article-title":"ITPA gene variants and anemia during telaprevir\/peginterferon\/ribavirin combination therapy in patients with chronic hepatitis C infection","volume":"60","author":"Tuefferd","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0570|cit570","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2014.01.013","article-title":"Risk factors predictive of anemia development during telaprevir plus peginterferon\/ribavirin therapy in treatment-experienced patients","volume":"60","author":"Witek","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0571|cit571","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/hep.26437","article-title":"Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial","volume":"58","author":"Younossi","year":"2013","journal-title":"Hepatology"},{"issue":"25","key":"10.1002\/14651858.CD012143.pub3-BIB0572|cit572","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0573|cit573","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(11)60007-X","article-title":"REALIZE trial final results: telaprevir-based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon\/ribavirin","volume":"54","author":"Zeuzem","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0574|cit574","doi-asserted-by":"crossref","first-page":"S661","DOI":"10.1016\/S0168-8278(15)31058-8","article-title":"Ombitasvir\/paritaprevir\/ritonavir and dasabuvir with ribavirin (RBV) has mild impact on health-related quality of life (HRQoL) compared with placebo during 12-week treatment in treatment-experienced adults with chronic hepatitis C (CHC)","volume":"62","author":"Liu","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"17","key":"10.1002\/14651858.CD012143.pub3-BIB0575|cit575","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0576|cit576","first-page":"563A","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis (AGATE-I)","volume":"62","author":"Asselah","year":"2015","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0577|cit577","doi-asserted-by":"crossref","unstructured":"Wyles D Ruane P Sulkowski M Dieterich D Luetkemeyer A Morgan T Daclatasvir in combination with sofosbuvir for HIV\/HCV coinfection: ALLY-2 study Topics in Antiviral Medicine 2015 62","DOI":"10.1016\/S0168-8278(15)30155-0"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0578|cit578","first-page":"741A","article-title":"Interferon-free regimen containing setrobuvir (STV) in combination with ritonavir-boosted danoprevir (DNVr) and ribavirin (R) with or without mericitabine (MCB) in HCV genotype (G)1 treatment-naive patients: interim SVR4 results from the ANNAPURNA study","volume":"58","author":"Jensen","year":"2013","journal-title":"Hepatology"},{"issue":"Spec No 1","key":"10.1002\/14651858.CD012143.pub3-BIB0579|cit579","first-page":"74","article-title":"APRICOT Study evaluated. Surprisingly high virologic response in HIV-HCV coinfection","volume":"146","author":"APRICOT Study Group","year":"2004","journal-title":"MMW Fortschritte der Medizin"},{"issue":"9883","key":"10.1002\/14651858.CD012143.pub3-BIB0580|cit580","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial","volume":"381","author":"Kowdley","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0581|cit581","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40268-015-0109-5","article-title":"Determinant factors of the direct medical costs associated with genotype 1 hepatitis C infection in treatment-experienced patients","volume":"15","author":"Akpo","year":"2015","journal-title":"Drugs in R&D"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0583|cit582","first-page":"S397","article-title":"A phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study","volume":"8","author":"Reddy","year":"2014","journal-title":"Hepatology International"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0582|cit583","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(14)71002-3","article-title":"Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): A randomised, double-blind, non-inferiority phase 3 trial","volume":"15","author":"Reddy","year":"2015","journal-title":"Lancet Infectious Diseases"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0584|cit584","first-page":"25","article-title":"Simeprevir with PegIFN\/ribavirin for chronic HCV infection shortens time with patient reported symptoms and impairment in QoL: ATTAIN study results","volume":"21","author":"Scott","year":"2014","journal-title":"Journal of Viral Hepatitis"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0585|cit585","doi-asserted-by":"crossref","first-page":"A682","DOI":"10.1016\/j.jval.2014.08.2543","article-title":"Impact of simeprevir versus telaprevir triple therapy for chronic HCV infection on patient-reported outcomes in prior non-responders to peginterferon\/ribavirin results from the phase III attain study","volume":"17","author":"Scott","year":"2014","journal-title":"Value in Health"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0586|cit586","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/cid\/ciu865","article-title":"Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with abt-450\/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the aviator study","volume":"60","author":"Poordad","year":"2015","journal-title":"Clinical Infectious Diseases"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0587|cit587","first-page":"S","article-title":"Treatment satisfaction in clinical trial (AVIATOR) patients treated with interferon-free, oral DAA regimens: external validation of the hepatitis C virus (HCV) treatment satisfaction (HCVTSat) instrument","volume":"146","author":"Szeinbach","year":"2014","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0588|cit588","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.14309\/00000434-201410002-00606","article-title":"Simeprevir and sofosbuvir with modified doses of ribavirin (RBV) therapy on telaprevir-experienced, coinfected (with HIV) cirrhotics with chronic hepatitis C (CHC): a randomized, open-label, clinical pilot study, STOP C, interim results","volume":"109","author":"Basu","year":"2014","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0589|cit589","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4997\/JRCPE.2011.222","article-title":"Boceprevir for previously treated chronic hepatitis C virus genotype I infection","volume":"41","author":"Bathgate","year":"2011","journal-title":"Journal of the Royal College of Physicians of Edinburgh"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD012143.pub3-BIB0590|cit590","first-page":"19","article-title":"Projecting the clinical impact of therapeutic regimens including boceprevir in previously untreated adult subjects with chronic hepatitis C genotype 1","volume":"26","author":"Bognar","year":"2011","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0591|cit591","first-page":"S57","article-title":"Efficacy safety and pharmacokinetics of 12 weeks of simeprevir in combination with TMC647055 ritonavir and JNJ 56914845 in genotype 1 hepatitis C virus infected patients","volume":"9","author":"Bourgeois","year":"2015","journal-title":"Hepatology International"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0592|cit592","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/S0168-8278(06)80561-1","article-title":"Safety and pharmacokinetics of the non-nucleoside polymerase inhibitor, HCV-796: results of a randomized, double-blind, placebo-controlled, ascending single-dose study in healthy subjects","volume":"44","author":"Chandra","year":"2006","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0593|cit593","doi-asserted-by":"crossref","first-page":"S362","DOI":"10.1016\/S0168-8278(13)60883-1","article-title":"High SVR rates (SVR4) for 12-week total telaprevir combination therapy in IL28B CC treatment-naives and prior relapsers with G1 chronic hepatitis C: concise interim analysis","volume":"58","author":"Nelson","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"9956","key":"10.1002\/14651858.CD012143.pub3-BIB0594|cit594","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0595|cit595","doi-asserted-by":"crossref","first-page":"A510","DOI":"10.1016\/j.jval.2015.09.1469","article-title":"Projected clinical and economic impact of grazoprevir (GZR, MK-5172)\/elbasvir (EBR, MK-8742) for chronic HCV genotype 1 infection in chronic kidney disease","volume":"18","author":"Elbasha","year":"2015","journal-title":"Value in Health"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0596|cit596","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0168-8278(15)30156-2","article-title":"C-surfer: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease","volume":"62","author":"Roth","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"10003","key":"10.1002\/14651858.CD012143.pub3-BIB0597|cit597","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"issue":"9973","key":"10.1002\/14651858.CD012143.pub3-BIB0598|cit598","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","article-title":"Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial","volume":"385","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0599|cit599","first-page":"244A","article-title":"High efficacy and safety of the all-oral combination regimen, MK-5172\/MK-8742 +\/- RBV for 12 weeks in HCV genotype 1 infected patients: the C-WORTHY study","volume":"48","author":"Lawitz","year":"2013","journal-title":"Hepatology"},{"issue":"9973","key":"10.1002\/14651858.CD012143.pub3-BIB0600|cit600","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","article-title":"Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV\/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial","volume":"385","author":"Sulkowski","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0601|cit601","unstructured":"Sulkowski M Mallolas J Bourliere M Gerstoft J Shibolet O Nahass R On-treatment viral response to MK-5172\/MK-8742 +\/- RBV for 12 weeks in HCV\/HIV-coinfected patients Topics in Antiviral Medicine 2014 324 5"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0602|cit602","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/MEG.0000000000000084","article-title":"VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection","volume":"26","author":"Bisceglie","year":"2014","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0603|cit603","first-page":"S195","article-title":"Simeprevir (TMC435) with peg-interferon\/ribavirin for treatment of chronic HCV genotype 1 infection in treatment naive patients: efficacy in patients with genotype 1b HCV in the QUEST-1 and-2 phase III trials","volume":"8","author":"Dore","year":"2014","journal-title":"Hepatology International"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0604|cit604","first-page":"562A","article-title":"Safety and tolerability of grazoprevir\/elbasvir in patients with chronic hepatitis C (HCV) infection: integrated analysis of phase 2-3 trials","volume":"62","author":"Dusheiko","year":"2015","journal-title":"Hepatology"},{"issue":"21","key":"10.1002\/14651858.CD012143.pub3-BIB0605|cit605","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0606|cit606","doi-asserted-by":"crossref","first-page":"S909","DOI":"10.1016\/S0016-5085(11)63772-4","article-title":"Projecting the clinical impact of therapeutic regimens including boceprevir in previously untreated adult subjects with chronic hepatitis C genotype 1","volume":"140","author":"Ferrante","year":"2011","journal-title":"Gastroenterology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0607|cit607","first-page":"795A","article-title":"Cost-effectiveness of boceprevir based regimens in previously untreated adult subjects with chronic hepatitis C genotype 1","volume":"54","author":"Ferrante","year":"2011","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0608|cit608","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2334-13-190","article-title":"Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modelling study","volume":"13","author":"Ferrante","year":"2013","journal-title":"BMC Infectious Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0609|cit609","first-page":"A5","article-title":"Final results from telaprevir phase II studies in genotype 1 treatment-naive or experienced subjects with chronic hepatitis C","volume":"59","author":"Foster","year":"2010","journal-title":"Gut"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0610|cit610","first-page":"556A","article-title":"Short-duration therapy with daclatasvir\/asunaprevir\/beclabuvir fixed-dose combination plus sofosbuvir in patients with chronic hepatitis C genotype 1 (FOURward study)","volume":"62","author":"Sulkowski","year":"2015","journal-title":"Hepatology"},{"issue":"20","key":"10.1002\/14651858.CD012143.pub3-BIB0611|cit611","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0612|cit612","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1111\/liv.12334","article-title":"A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects","volume":"34","author":"Gardner","year":"2014","journal-title":"Liver International"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0613|cit613","first-page":"1150A","article-title":"HCVerso1: a phase III study of faldaprevir (FDV) plus deleobuvir (DBV) and ribavirin (RBV) for chronic HCV genotype (GT)-1b infection in treatment-naive patients","volume":"59","author":"Sarrazin","year":"2014","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0614|cit614","first-page":"1155A","article-title":"HCVerso2: a phase III study of faldaprevir (FDV) plus deleobuvir (DBV) and ribavirin (RBV) for chronic HCV genotype (GT)-1b infection in treatment-naive patients including those ineligible for pegylated interferon (PegIFN)","volume":"59","author":"Nelson","year":"2014","journal-title":"Hepatology"},{"issue":"20","key":"10.1002\/14651858.CD012143.pub3-BIB0615|cit615","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0616|cit616","first-page":"756A","article-title":"Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-na\u00efve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST 1 and 2 phase III trials","volume":"58","author":"Jacobson","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0617|cit617","first-page":"559A","article-title":"Efficacy, safety and pharmacokinetics of grazoprevir (MK-5172) and elbasvir (MK-8742) In hepatitis C genotype 1 infected non-cirrhotic Japanese patients (phase 2 portion in phase 2\/3 combined study)","volume":"62","author":"Kawada","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0618|cit618","first-page":"A227","article-title":"Ribavirin does not impact health-related quality of life (HRQoL) in patients on ombitasvir\/paritaprevir\/ritonavir and dasabuvir at the end of 12-week treatment in treatment-naive adults with genotype 1a (GT1a) chronic hepatitis C","volume":"18","author":"Liu","year":"2015","journal-title":"Value in Health"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0619|cit619","first-page":"877A","article-title":"Combination therapy with BMS-790052 and BMS-650032 alone or with pegIFN\/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders","volume":"52","author":"Lok","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0620|cit620","doi-asserted-by":"crossref","first-page":"S536","DOI":"10.1016\/S0168-8278(11)61358-5","article-title":"Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN\/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders","volume":"54","author":"Lok","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0621|cit621","doi-asserted-by":"crossref","first-page":"S557","DOI":"10.1016\/S0168-8278(12)61426-3","article-title":"Confirmation that quadruple therapy with daclatasvir (NS5A inhibitor), asunaprevir (NS3 inhibitor) and peginterferon\/ribavirin results in high rate of svr4 in HCV genotype 1 null responders","volume":"56","author":"Lok","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0622|cit622","first-page":"230A","article-title":"Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A Inhibitor) and asunaprevir (ASV; NS3 Inhibitor) with or without peginterferon alfa-2a\/ribavirin (PEG\/RBV)","volume":"56","author":"Lok","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0623|cit623","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.10.019","article-title":"Randomized trial of daclatasvir and asunaprevir with or without PegIFN\/RBV for hepatitis C virus genotype 1 null responders","volume":"60","author":"Lok","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0624|cit624","doi-asserted-by":"crossref","first-page":"S1001","DOI":"10.1016\/S0016-5085(15)33418-1","article-title":"Malachite-I: phase 3b trial of ombitasvir\/paritaprevir\/r and dasabuvir plus \/- ribavirin or telaprevir plus peginterferon\/ribavirin in treatment-naive adults with HCV genotype 1","volume":"148","author":"Conway","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0625|cit625","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jhep.2015.08.015","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the malachite-I\/II trials","volume":"64","author":"Dore","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0626|cit626","first-page":"802A","article-title":"Better work productivity and activity in patients on ombitasvir\/ paritaprevir\/ritonavir and dasabuvir with or without ribavirin (3D+RBV or 3D) in treatment-naive adults with genotype 1 (GT1) chronic hepatitis C","volume":"62","author":"Liu","year":"2015","journal-title":"Hepatology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0627|cit627","doi-asserted-by":"crossref","first-page":"S656","DOI":"10.1016\/S0168-8278(15)31049-7","article-title":"Malachite-II: phase 3B trial of ombitasvir\/paritaprevir\/R and dasabuvir + ribavirin or telaprevir + peginterferon\/ribavirin in peginterferon\/ribavirin treatment-experienced adults with HCV genotype 1","volume":"62","author":"Dore","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0628|cit628","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jhep.2015.08.015","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the malachite-I\/II trials","volume":"64","author":"Dore","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0629|cit629","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/liv.12300","article-title":"Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2\/3 clinical trials","volume":"34","author":"Manns","year":"2014","journal-title":"Liver International"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0630|cit630","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1016\/S0168-8278(15)30003-9","article-title":"Ledipasvir\/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective SOLAR 2 trial","volume":"62","author":"Manns","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0631|cit631","first-page":"S186","article-title":"Safety of asunaprevir (ASV) in the all-oral dual combination with daclatasvir (DCV) or in combination with peginterferon\/ribavirin (pegIFN\/RBV) for chronic HCV infection","volume":"59","author":"Mendez","year":"2014","journal-title":"Hepatology International"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0632|cit632","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"Mizokami","year":"2015","journal-title":"Lancet Infectious Diseases"},{"issue":"9973","key":"10.1002\/14651858.CD012143.pub3-BIB0633|cit633","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(14)62483-1","article-title":"Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study","volume":"385","author":"Molina","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0634|cit634","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/hep.24549","article-title":"Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response","volume":"54","author":"Muir","year":"2011","journal-title":"Hepatology"},{"issue":"e-1","key":"10.1002\/14651858.CD012143.pub3-BIB0635|cit635","first-page":"301","article-title":"Unity-2: daclatasvir\/asunaprevir\/beclabuvir +\/- RBV for HCV genotype 1 with cirrhosis","volume":"23","author":"Muir","year":"2015","journal-title":"Topics in Antiviral Medicine"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0636|cit636","first-page":"S47","article-title":"Fixed dose oral combination therapy with daclatasvir asunaprevir beclabuvir-ribavirin for patients with chronic HCV genotype 1 infection and compensated cirrhosis unity 2 phase 3 results","volume":"9","author":"Muir","year":"2015","journal-title":"Hepatology International"},{"issue":"17","key":"10.1002\/14651858.CD012143.pub3-BIB0637|cit637","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2015.3868","article-title":"Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis","volume":"313","author":"Muir","year":"2015","journal-title":"JAMA"},{"issue":"20","key":"10.1002\/14651858.CD012143.pub3-BIB0638|cit638","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0639|cit639","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/liv.12254","article-title":"Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection","volume":"34","author":"Nishiguchi","year":"2014","journal-title":"Liver International"},{"issue":"22","key":"10.1002\/14651858.CD012143.pub3-BIB0640|cit640","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.2169\/internalmedicine.53.2366","article-title":"Weight loss during telaprevir-based triple therapy due to telaprevir-induced appetite loss","volume":"53","author":"Nomura","year":"2014","journal-title":"Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012143.pub3-BIB0641|cit641","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jvh.12091","article-title":"All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear)","volume":"20","author":"Lawitz","year":"2013","journal-title":"Journal of Viral Hepatitis"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0642|cit642","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/S0168-8278(15)30168-9","article-title":"A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1","volume":"62","author":"Kwo","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0643|cit643","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1053\/j.gastro.2013.11.047","article-title":"Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C","volume":"146","author":"Buti","year":"2013","journal-title":"Gastroenterology"},{"issue":"Suppl1","key":"10.1002\/14651858.CD012143.pub3-BIB0644|cit644","doi-asserted-by":"crossref","first-page":"S326","DOI":"10.1016\/S0168-8278(13)60800-4","article-title":"Efficacy of telaprevir dosed twice daily versus every 8 hours by IL28B genotype: results from phase III OPTIMIZE study","volume":"58","author":"Buti","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD012143.pub3-BIB0645|cit645","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1111\/liv.12931","article-title":"Ombitasvir\/paritaprevir\/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia","volume":"35","author":"Forns","year":"2015","journal-title":"Liver International"},{"issue":"21","key":"10.1002\/14651858.CD012143.pub3-BIB0646|cit646","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0647|cit647","doi-asserted-by":"crossref","first-page":"S637","DOI":"10.1016\/S0168-8278(15)31011-4","article-title":"Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir\/paritaprevir\/r, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis","volume":"62","author":"Wedwemeyer","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0648|cit648","doi-asserted-by":"crossref","first-page":"S320","DOI":"10.1016\/S0168-8278(08)60856-9","article-title":"Results of a safety, tolerability and pharmacokinetic phase I study of VCH-916, a novel polymerase inhibitor for HCV, following single ascending doses in healthy volunteers","volume":"48","author":"Proulx","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0649|cit649","first-page":"814A","article-title":"An evaluation of neutropenia in the pivotal studies of boceprevir (BOC) plus PegInterferon alfa-2B\/ribavirin (PR)","volume":"54","author":"Reddy","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012143.pub3-BIB0650|cit650","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/S1590-8658(11)60061-3","article-title":"Impact of insulin resistance on antiviral efficacy of telaprevir-based regimen in treatment-naive genotype 1 HCV: results from C208 sub-analysis","volume":"43","author":"Carosi","year":"2011","journal-title":"Digestive and Liver Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0651|cit651","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1590-8658(10)60385-4","article-title":"Telaprevir (TVR) q8h or q12h combined with either peginterferon (PEG-IFN, P) alfa-2a or alfa-2b and ribavirin (RBV, r) in treatment-naive genotype 1 hepatitis C: final results of the randomized, open-label, multicenter phase 2 study C208","volume":"42","author":"Colombo","year":"2010","journal-title":"Digestive and Liver Disease"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0652|cit652","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(10)60058-X","article-title":"On-treatment response-guided therapy with telaprevir q8h or q12h combined with peginterferon alfa-2a or peginterferon alfa-2b and ribavirin in treatment-naive genotype 1 hepatitis C (study c208)","volume":"52","author":"Forns","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0653|cit653","first-page":"1136A","article-title":"Phase 2 study of telaprevir administered q8h or q12h with peginterferon-alfa-2a or -alfa-2b and ribavirin in treatment-naive subjects with genotype 1 hepatitis C: week 4 interim results","volume":"48","author":"Forns","year":"2008","journal-title":"Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0654|cit654","first-page":"S847","article-title":"On-treatment response-guided therapy with telaprevir Q8h or Q12h combined with peginterferon alfa-2a or peginterferon alfa-2b and ribavirin in treatment-naive genotype 1 hepatitis C (Study C208)","volume":"138","author":"Marcellin","year":"2010","journal-title":"Gastroenterology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0655|cit655","first-page":"395A","article-title":"Virological analysis of patients receiving telaprevir administered q8h or q12h with peginterferon-alfa-2a or -alfa- 2b and ribavirin in treatment - naive patients with genotype 1 hepatitis C: study C208","volume":"50","author":"Marcellin","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0656|cit656","first-page":"61","article-title":"Telaprevir Q8H or Q12H combined with either peginterferon (PEG-IFN, P) alfa-2a or alfa-2b and ribavirin (RBV, R) in treatment-naive genotype 1 hepatitis C patients: Final results of the randomized, open-label, multicenter phase 2 study C208","volume":"4","author":"Marcellin","year":"2010","journal-title":"Hepatology International"},{"issue":"10","key":"10.1002\/14651858.CD012143.pub3-BIB0657|cit657","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1136\/gutjnl-2011-300749","article-title":"Insulin resistance and response to telaprevir plus peginterferon a and ribavirin in treatment-naive patients infected with HCV genotype 1","volume":"61","author":"Serfaty","year":"2012","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012143.pub3-BIB0658|cit658","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1016\/S0168-8278(11)60478-9","article-title":"Anemia during treatment with peginterferon alfa-2b\/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment-failure patients","volume":"54","author":"Sulkowski","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0659|cit659","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1016\/S0168-8278(12)61174-X","article-title":"Ribavirin dose modification in treatment-naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies","volume":"56","author":"Sulkowski","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0660|cit660","first-page":"298A","article-title":"Complete SVR4 rates in treatment-naive HCV genotype 1a and 1b patients who achieved vRVR with an interferon-free all-oral regimen","volume":"56","author":"Sulkowski","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0661|cit661","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1016\/S0168-8278(10)61191-9","article-title":"Silen-C2: early antiviral activity and safety of BI 201335 combined with peginterferon alfa-2A and ribavirin (PegIfn\/Rbv) in chronic HCV genotype-1 patients with non-response to PegIfn\/Rbv","volume":"52","author":"Sulkowski","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0662|cit662","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/hep.26386","article-title":"Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0663|cit663","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(11)60068-8","article-title":"Silen-C2: sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alfa-2A and ribavirin (P\/R) in chronic HCV genotype-1 patients with non-response to P\/R","volume":"54","author":"Sulkowski","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0664|cit664","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0665|cit665","first-page":"1436A","article-title":"Virologic response to an interferon-free regimen of BI201335 and BI207127, with and without ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: week 12 interim results of the sound-C2 study","volume":"54","author":"Zeuzem","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl S2","key":"10.1002\/14651858.CD012143.pub3-BIB0666|cit666","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S0168-8278(12)60115-9","article-title":"SVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127, +\/-ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of sound-C2","volume":"56","author":"Zeuzem","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD012143.pub3-BIB0667|cit667","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3851\/IMP2567","article-title":"Faldaprevir (BI201335), deleobuvir (BI207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results","volume":"18","author":"Zeuzem","year":"2013","journal-title":"Antiviral Therapy"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0668|cit668","first-page":"486A","article-title":"High sustained virologic response following interferon-free treatment of chronic HCV GT1 infection for 4 weeks with HCV protease inhibitor BI201335, polymerase inhibitor BI207127 and ribavirin, followed by BI201335 and pegifn\/ribavirin the sound-C1 study","volume":"54","author":"Zeuzem","year":"2011","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0669|cit669","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jhep.2014.04.003","article-title":"Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study","volume":"61","author":"Younossi","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012143.pub3-BIB0670|cit670","first-page":"733A","article-title":"Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial","volume":"58","author":"Zeuzem","year":"2013","journal-title":"Hepatology"},{"issue":"21","key":"10.1002\/14651858.CD012143.pub3-BIB0671|cit671","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"S1","key":"10.1002\/14651858.CD012143.pub3-BIB0672|cit672","first-page":"310A","article-title":"First report of peginterferon lambda\/ribavirin in combination with either daclatasvir or asunaprevir in HCV genotype 1 Japanese subjects: early sustained virologic response (SVR4) results from the D-LITE Japanese sub-study","volume":"56","author":"Izumi","year":"2012","journal-title":"Hepatology"},{"issue":"1 Suppl S","key":"10.1002\/14651858.CD012143.pub3-BIB0673|cit673","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/S0168-8278(14)61382-9","article-title":"A phase II study of samatasvir (IDX719) in combination with simeprevir and ribavirin in treatment-naive HCV-infected subjects with genotypes 1B and 4 (helix-1 study)","volume":"60","author":"Lawitz","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"20","key":"10.1002\/14651858.CD012143.pub3-BIB0674|cit674","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"10.1002\/14651858.CD012143.pub3-BIB0675|cit675","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0676|cit676","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0677|cit677","first-page":"355","article-title":"Sofosbuvir-ribavirin duo for chronic hepatitis C","volume":"78","author":"Basile","year":"2014","journal-title":"Connecticut Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0678|cit678","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.idc.2012.08.010","article-title":"IL28B polymorphisms as a pre-treatment predictor of response to HCV treatment","volume":"26","author":"Berger","year":"2012","journal-title":"Infectious Disease Clinics of North America"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0679|cit679","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005527.pub2","article-title":"Ribavirin monotherapy for chronic hepatitis C","author":"Brok","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0680|cit680","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005445.pub2","article-title":"Ribavirin plus interferon versus interferon for chronic hepatitis C","author":"Brok","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"RR-19","key":"10.1002\/14651858.CD012143.pub3-BIB0681|cit681","first-page":"1","article-title":"Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease","volume":"47","author":"Centers for Disease Control and Prevention","year":"1998","journal-title":"MMWR. Recommendations and Reports: Morbidity and Mortality Weekly Report"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0682|cit682","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 Statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0683|cit683","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.clinthera.2014.12.012","article-title":"Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection","volume":"37","author":"Childs-Kean","year":"2015","journal-title":"Clinical Therapeutics"},{"issue":"4902","key":"10.1002\/14651858.CD012143.pub3-BIB0684|cit684","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0685|cit685","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jval.2016.10.011","article-title":"Time to review the role of surrogate end points in health policy: state of the art and the way forward","volume":"20","author":"Ciani","year":"2017","journal-title":"Value Health"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0686|cit686","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1478-3231.2011.02711.x","article-title":"The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C","volume":"32","author":"Clark","year":"2012","journal-title":"Liver International"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0687|cit687","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.dld.2013.08.243","article-title":"Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF)","volume":"46","author":"Coco","year":"2014","journal-title":"Digestive and Liver Disease"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0688|cit688","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2013.08.019","article-title":"Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents","volume":"68","author":"Conteduca","year":"2014","journal-title":"Journal of Infection"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0689|cit689","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0690|cit690","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012143.pub3-BIB0691|cit691","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jhep.2014.06.031","article-title":"Virology and cell biology of the hepatitis C virus life cycle: an update","volume":"61","author":"Dubuisson","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0692|cit692","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL Recommendations on Treatment of Hepatitis C","volume":"63","author":"European Association for Study of Liver","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"7109","key":"10.1002\/14651858.CD012143.pub3-BIB0693|cit693","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0694|cit694","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection","volume":"64","author":"El-Serag","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012143.pub3-BIB0695|cit695","doi-asserted-by":"crossref","first-page":"301-10","DOI":"10.1016\/j.jare.2014.11.004","article-title":"New era for management of chronic hepatitis C virus using direct antiviral agents: a review","volume":"6","author":"Elbaz","year":"2015","journal-title":"Journal of Advanced Research"},{"issue":"17","key":"10.1002\/14651858.CD012143.pub3-BIB0696|cit696","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.4254\/wjh.v7.i17.2100","article-title":"New treatment strategies for hepatitis C infection","volume":"7","author":"Ermis","year":"2015","journal-title":"World Journal of Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0697|cit697","author":"Engeneering & Biotechnology News","year":"2017","journal-title":"FiercePharma, annual Reports, company websites, SEC Filings and press releases"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0698|cit698","article-title":"Surrogate end points in clinical trials: Are we being misled?","author":"Fleming","journal-title":"Annals of Internal Medicine 1996, 125(7):605-613."},{"key":"10.1002\/14651858.CD012143.pub3-BIB0699|cit699","article-title":"Biomarkers and surrogate endpoints in clinical trials","author":"Fleming","journal-title":"Statistics in medicine 2012, 31(25):2973-2984."},{"key":"10.1002\/14651858.CD012143.pub3-BIB0700|cit700","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejim.2016.03.020","article-title":"Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them","volume":"32","author":"Garattini","year":"2016","journal-title":"European Journal of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0701|cit701","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0702|cit702","unstructured":"Gluud C Nikolova D Klingenberg SL Cochrane Hepato-Biliary Group About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 2. Art. No.: LIVER"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0703|cit703","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0704|cit704","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0705|cit705","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0706|cit706","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD012143.pub3-BIB0707|cit707","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence--publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD012143.pub3-BIB0708|cit708","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence--imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD012143.pub3-BIB0709|cit709","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence--inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD012143.pub3-BIB0710|cit710","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence--indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD012143.pub3-BIB0711|cit711","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","article-title":"GRADE guidelines: 9. Rating up the quality of evidence","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0712|cit712","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0713|cit713","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0714|cit714","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0715|cit715","doi-asserted-by":"crossref","first-page":"338-51","DOI":"10.1038\/nrgastro.2016.60","article-title":"Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights","volume":"13","author":"G\u00f6tte","year":"2016","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"issue":"20","key":"10.1002\/14651858.CD012143.pub3-BIB0716|cit716","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0717|cit717","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005441.pub3","article-title":"Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C","author":"Hauser","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0718|cit718","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0719|cit719","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.Cochrane.org"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0720|cit720","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0721|cit721","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0722|cit722","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"25","key":"10.1002\/14651858.CD012143.pub3-BIB0723|cit723","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0724|cit724","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2288-14-120","article-title":"Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0725|cit725","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2288-14-34","article-title":"The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0726|cit726","doi-asserted-by":"crossref","unstructured":"Jakobsen JC Wetterslev J Lange T Gluud C Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews [editorial] Cochrane Database of Systematic Reviews 2016 10.1002\/14651858.ED000111 10.1002\/14651858.ED000111","DOI":"10.1002\/14651858.ED000111"},{"issue":"4","key":"10.1002\/14651858.CD012143.pub3-BIB0727|cit727","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012143","article-title":"Direct-acting antivirals for chronic hepatitis C","author":"Jakobsen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0728|cit728","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","author":"Kemp","journal-title":"BMC Medicine 2017, 15(1):134."},{"issue":"11","key":"10.1002\/14651858.CD012143.pub3-BIB0729|cit729","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0730|cit730","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003617.pub2","article-title":"Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C","author":"Koretz","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0731|cit731","first-page":"g7809","article-title":"Is widespread screening for hepatitis C justified?","volume":"350","author":"Koretz","year":"2015","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0732|cit732","unstructured":"Koretz R Direct-acting antivirals: do they work beyond sustained virological response in chronic hepatitis C patients? EASL 2016"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0733|cit733","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2169\/internalmedicine.52.8156","article-title":"The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials","volume":"52","author":"Lang","year":"2013","journal-title":"Internal Medicine"},{"issue":"20","key":"10.1002\/14651858.CD012143.pub3-BIB0734|cit734","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD012143.pub3-BIB0735|cit735","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub2","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD012143.pub3-BIB0736|cit736","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating viral hepatitis C: efficacy, side effects, and complications","volume":"55","author":"Manns","year":"2006","journal-title":"Gut"},{"issue":"9963","key":"10.1002\/14651858.CD012143.pub3-BIB0737|cit737","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0738|cit738","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"issue":"9128","key":"10.1002\/14651858.CD012143.pub3-BIB0739|cit739","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0740|cit740","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0741|cit741","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/adc.2004.059436","article-title":"When does mother to child transmission of hepatitis C virus occur?","volume":"90","author":"Mok","year":"2005","journal-title":"Archives of Disease in Childhood. Fetal and Neonatal Edition"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0742|cit742","doi-asserted-by":"crossref","first-page":"736-42; quiz 74","DOI":"10.1016\/j.jclinepi.2013.02.004","article-title":"The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses","volume":"66","author":"Mustafa","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0743|cit743","unstructured":"NICE Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C www.nice.org.uk\/guidance\/ta75NICE.org"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0744|cit744","unstructured":"NICE Sofosbuvir for treating chronic hepatitis C www.nice.org.uk\/guidance\/ta330\/chapter\/2-The-technology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0745|cit745","unstructured":"Pockros PJ Direct-acting antivirals for the treatment of hepatitis C virus infection www.uptodate.com\/contents\/direct-acting-antivirals-for-the-treatment-of-hepatitis-c-virus-infection?source=search_result&search=Direct-acting+antivirals+for+the+treatment+of+hepatitis+C+virus+infection&selectedTitle=1\u02dc150"},{"issue":"13","key":"10.1002\/14651858.CD012143.pub3-BIB0746|cit746","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0747|cit747","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2893.2012.01617.x","article-title":"Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents","volume":"19","author":"Poordad","year":"2012","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0748|cit748","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","author":"Reig","journal-title":"J Hepatol. 2016;65(4):719-26."},{"key":"10.1002\/14651858.CD012143.pub3-BIB0749|cit749","article-title":"Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?","author":"Reig","journal-title":"Semin Liver Dis. 2017;37(2):109-18."},{"key":"10.1002\/14651858.CD012143.pub3-BIB0750|cit750","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"38","key":"10.1002\/14651858.CD012143.pub3-BIB0751|cit751","doi-asserted-by":"crossref","first-page":"10760","DOI":"10.3748\/wjg.v21.i38.10760","article-title":"Impact of new treatment options for hepatitis C virus infection in liver transplantation","volume":"21","author":"Righi","year":"2015","journal-title":"World Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD012143.pub3-BIB0752|cit752","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.3390\/v7092864","article-title":"Interferon-free hepatitis C treatment before and after liver transplantation: the role of HCV drug resistance","volume":"7","author":"Roche","year":"2015","journal-title":"Viruses"},{"issue":"6","key":"10.1002\/14651858.CD012143.pub3-BIB0753|cit753","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"35","key":"10.1002\/14651858.CD012143.pub3-BIB0754|cit754","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"7","key":"10.1002\/14651858.CD012143.pub3-BIB0755|cit755","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"Scheel","year":"2013","journal-title":"Nature Medicine"},{"issue":"11","key":"10.1002\/14651858.CD012143.pub3-BIB0756|cit756","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012143.pub3-BIB0757|cit757","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0758|cit758","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"19","key":"10.1002\/14651858.CD012143.pub3-BIB0759|cit759","article-title":"Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits","volume":"15","author":"Smith-Palmer","year":"2015","journal-title":"BMC Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD012143.pub3-BIB0760|cit760","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/cid\/cis616","article-title":"Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence","volume":"55","author":"Spradling","year":"2012","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0761|cit761","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention . Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"9","key":"10.1002\/14651858.CD012143.pub3-BIB0762|cit762","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012143.pub3-BIB0763|cit763","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"issue":"7265","key":"10.1002\/14651858.CD012143.pub3-BIB0764|cit764","doi-asserted-by":"crossref","first-page":"798-801","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0765|cit765","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual for Trial Sequential Analysis (TSA) ctu.dk\/tsa\/files\/tsa_manual.pdf"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0766|cit766","unstructured":"Copenhagen Trial Unit TSA - Trial Sequential Analysis 2011"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0767|cit767","first-page":"w14093","article-title":"Hepatitis C: a changing epidemic","volume":"145","author":"Wandeler","year":"2015","journal-title":"Swiss Medical Weekly"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0768|cit768","article-title":"Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents","author":"Wang","journal-title":"Clin Gastroenterol Hepatol 2017; 15:132-6"},{"issue":"1","key":"10.1002\/14651858.CD012143.pub3-BIB0769|cit769","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0770|cit770","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0771|cit771","unstructured":"WHO Hepatitis C Fact sheet N\u00b0164 www.who.int\/mediacentre\/factsheets\/fs164\/en\/"},{"key":"10.1002\/14651858.CD012143.pub3-BIB0772|cit772","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"366","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"8","key":"10.1002\/14651858.CD012143.pub3-BIB0773|cit773","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"New England Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD012143.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T20:06:23Z","timestamp":1750881983000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012143.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,18]]},"references-count":773,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012143.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,18]]}}}